A 6.6-kDa protein component of VERY-LOW-DENSITY LIPOPROTEINS; INTERMEDIATE-DENSITY LIPOPROTEINS; and HIGH-DENSITY LIPOPROTEINS. Apo C-I displaces APO E from lipoproteins, modulate their binding to receptors (RECEPTORS, LDL), and thereby decrease their clearance from plasma. Elevated Apo C-I levels are associated with HYPERLIPOPROTEINEMIA and ATHEROSCLEROSIS.
A group of apolipoproteins that can readily exchange among the various classes of lipoproteins (HDL; VLDL; CHYLOMICRONS). After lipolysis of TRIGLYCERIDES on VLDL and chylomicrons, Apo-C proteins are normally transferred to HDL. The subtypes can modulate remnant binding to receptors, LECITHIN CHOLESTEROL ACYLTRANSFERASE, or LIPOPROTEIN LIPASE.
A 9-kDa protein component of VERY-LOW-DENSITY LIPOPROTEINS and CHYLOMICRON REMNANTS. Apo C-III, synthesized in the liver, is an inhibitor of LIPOPROTEIN LIPASE. Apo C-III modulates the binding of chylomicron remnants and VLDL to receptors (RECEPTORS, LDL) thus decreases the uptake of triglyceride-rich particles by the liver cells and subsequent degradation. The normal Apo C-III is glycosylated. There are several polymorphic forms with varying amounts of SIALIC ACID (Apo C-III-0, Apo C-III-1, and Apo C-III-2).
A class of lipoproteins of very light (0.93-1.006 g/ml) large size (30-80 nm) particles with a core composed mainly of TRIGLYCERIDES and a surface monolayer of PHOSPHOLIPIDS and CHOLESTEROL into which are imbedded the apolipoproteins B, E, and C. VLDL facilitates the transport of endogenously made triglycerides to extrahepatic tissues. As triglycerides and Apo C are removed, VLDL is converted to INTERMEDIATE-DENSITY LIPOPROTEINS, then to LOW-DENSITY LIPOPROTEINS from which cholesterol is delivered to the extrahepatic tissues.
The most abundant protein component of HIGH DENSITY LIPOPROTEINS or HDL. This protein serves as an acceptor for CHOLESTEROL released from cells thus promoting efflux of cholesterol to HDL then to the LIVER for excretion from the body (reverse cholesterol transport). It also acts as a cofactor for LECITHIN CHOLESTEROL ACYLTRANSFERASE that forms CHOLESTEROL ESTERS on the HDL particles. Mutations of this gene APOA1 cause HDL deficiency, such as in FAMILIAL ALPHA LIPOPROTEIN DEFICIENCY DISEASE and in some patients with TANGIER DISEASE.
A class of protein components which can be found in several lipoproteins including HIGH-DENSITY LIPOPROTEINS; VERY-LOW-DENSITY LIPOPROTEINS; and CHYLOMICRONS. Synthesized in most organs, Apo E is important in the global transport of lipids and cholesterol throughout the body. Apo E is also a ligand for LDL receptors (RECEPTORS, LDL) that mediates the binding, internalization, and catabolism of lipoprotein particles in cells. There are several allelic isoforms (such as E2, E3, and E4). Deficiency or defects in Apo E are causes of HYPERLIPOPROTEINEMIA TYPE III.
A 513-kDa protein synthesized in the LIVER. It serves as the major structural protein of low-density lipoproteins (LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL). It is the ligand for the LDL receptor (RECEPTORS, LDL) that promotes cellular binding and internalization of LDL particles.
Major structural proteins of triacylglycerol-rich LIPOPROTEINS. There are two forms, apolipoprotein B-100 and apolipoprotein B-48, both derived from a single gene. ApoB-100 expressed in the liver is found in low-density lipoproteins (LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL). ApoB-48 expressed in the intestine is found in CHYLOMICRONS. They are important in the biosynthesis, transport, and metabolism of triacylglycerol-rich lipoproteins. Plasma Apo-B levels are high in atherosclerotic patients but non-detectable in ABETALIPOPROTEINEMIA.
A major and the second most common isoform of apolipoprotein E. In humans, Apo E4 differs from APOLIPOPROTEIN E3 at only one residue 112 (cysteine is replaced by arginine), and exhibits a lower resistance to denaturation and greater propensity to form folded intermediates. Apo E4 is a risk factor for ALZHEIMER DISEASE and CARDIOVASCULAR DISEASES.
A 34-kDa glycosylated protein. A major and most common isoform of apolipoprotein E. Therefore, it is also known as apolipoprotein E (ApoE). In human, Apo E3 is a 299-amino acid protein with a cysteine at the 112 and an arginine at the 158 position. It is involved with the transport of TRIGLYCERIDES; PHOSPHOLIPIDS; CHOLESTEROL; and CHOLESTERYL ESTERS in and out of the cells.
The second most abundant protein component of HIGH DENSITY LIPOPROTEINS or HDL. It has a high lipid affinity and is known to displace APOLIPOPROTEIN A-I from HDL particles and generates a stable HDL complex. ApoA-II can modulate the activation of LECITHIN CHOLESTEROL ACYLTRANSFERASE in the presence of APOLIPOPROTEIN A-I, thus affecting HDL metabolism.
Protein components on the surface of LIPOPROTEINS. They form a layer surrounding the hydrophobic lipid core. There are several classes of apolipoproteins with each playing a different role in lipid transport and LIPID METABOLISM. These proteins are synthesized mainly in the LIVER and the INTESTINES.
A 9-kDa protein component of VERY-LOW-DENSITY LIPOPROTEINS. It contains a cofactor for LIPOPROTEIN LIPASE and activates several triacylglycerol lipases. The association of Apo C-II with plasma CHYLOMICRONS; VLDL, and HIGH-DENSITY LIPOPROTEINS is reversible and changes rapidly as a function of triglyceride metabolism. Clinically, Apo C-II deficiency is similar to lipoprotein lipase deficiency (HYPERLIPOPROTEINEMIA TYPE I) and is therefore called hyperlipoproteinemia type IB.
Structural proteins of the alpha-lipoproteins (HIGH DENSITY LIPOPROTEINS), including APOLIPOPROTEIN A-I and APOLIPOPROTEIN A-II. They can modulate the activity of LECITHIN CHOLESTEROL ACYLTRANSFERASE. These apolipoproteins are low in atherosclerotic patients. They are either absent or present in extremely low plasma concentration in TANGIER DISEASE.
One of three major isoforms of apolipoprotein E. In humans, Apo E2 differs from APOLIPOPROTEIN E3 at one residue 158 where arginine is replaced by cysteine (R158--C). In contrast to Apo E3, Apo E2 displays extremely low binding affinity for LDL receptors (RECEPTORS, LDL) which mediate the internalization and catabolism of lipoprotein particles in liver cells. ApoE2 allelic homozygosity is associated with HYPERLIPOPROTEINEMIA TYPE III.
A 241-kDa protein synthesized only in the INTESTINES. It serves as a structural protein of CHYLOMICRONS. Its exclusive association with chylomicron particles provides an indicator of intestinally derived lipoproteins in circulation. Apo B-48 is a shortened form of apo B-100 and lacks the LDL-receptor region.
A class of lipoproteins of small size (4-13 nm) and dense (greater than 1.063 g/ml) particles. HDL lipoproteins, synthesized in the liver without a lipid core, accumulate cholesterol esters from peripheral tissues and transport them to the liver for re-utilization or elimination from the body (the reverse cholesterol transport). Their major protein component is APOLIPOPROTEIN A-I. HDL also shuttle APOLIPOPROTEINS C and APOLIPOPROTEINS E to and from triglyceride-rich lipoproteins during their catabolism. HDL plasma level has been inversely correlated with the risk of cardiovascular diseases.
A large and highly glycosylated protein constituent of LIPOPROTEIN (A). It has very little affinity for lipids but forms disulfide-linkage to APOLIPOPROTEIN B-100. Apoprotein(a) has SERINE PROTEINASE activity and can be of varying sizes from 400- to 800-kDa. It is homologous to PLASMINOGEN and is known to modulate THROMBOSIS and FIBRINOLYSIS.
Lipid-protein complexes involved in the transportation and metabolism of lipids in the body. They are spherical particles consisting of a hydrophobic core of TRIGLYCERIDES and CHOLESTEROL ESTERS surrounded by a layer of hydrophilic free CHOLESTEROL; PHOSPHOLIPIDS; and APOLIPOPROTEINS. Lipoproteins are classified by their varying buoyant density and sizes.
The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils.
A lipoprotein that resembles the LOW-DENSITY LIPOPROTEINS but with an extra protein moiety, APOPROTEIN (A) also known as APOLIPOPROTEIN (A), linked to APOLIPOPROTEIN B-100 on the LDL by one or two disulfide bonds. High plasma level of lipoprotein (a) is associated with increased risk of atherosclerotic cardiovascular disease.
A glycoprotein component of HIGH-DENSITY LIPOPROTEINS that transports small hydrophobic ligands including CHOLESTEROL and STEROLS. It occurs in the macromolecular complex with LECITHIN CHOLESTEROL ACYLTRANSFERASE. Apo D is expressed in and secreted from a variety of tissues such as liver, placenta, brain tissue and others.
A class of lipoproteins of small size (18-25 nm) and light (1.019-1.063 g/ml) particles with a core composed mainly of CHOLESTEROL ESTERS and smaller amounts of TRIGLYCERIDES. The surface monolayer consists mostly of PHOSPHOLIPIDS, a single copy of APOLIPOPROTEIN B-100, and free cholesterol molecules. The main LDL function is to transport cholesterol and cholesterol esters to extrahepatic tissues.
A generic term for fats and lipoids, the alcohol-ether-soluble constituents of protoplasm, which are insoluble in water. They comprise the fats, fatty oils, essential oils, waxes, phospholipids, glycolipids, sulfolipids, aminolipids, chromolipids (lipochromes), and fatty acids. (Grant & Hackh's Chemical Dictionary, 5th ed)
Receptors on the plasma membrane of nonhepatic cells that specifically bind LDL. The receptors are localized in specialized regions called coated pits. Hypercholesteremia is caused by an allelic genetic defect of three types: 1, receptors do not bind to LDL; 2, there is reduced binding of LDL; and 3, there is normal binding but no internalization of LDL. In consequence, entry of cholesterol esters into the cell is impaired and the intracellular feedback by cholesterol on 3-hydroxy-3-methylglutaryl CoA reductase is lacking.
A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.
Cholesterol which is contained in or bound to high-density lipoproteins (HDL), including CHOLESTEROL ESTERS and free cholesterol.
Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.
A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances.
An autosomal recessively inherited disorder characterized by the accumulation of intermediate-density lipoprotein (IDL or broad-beta-lipoprotein). IDL has a CHOLESTEROL to TRIGLYCERIDES ratio greater than that of VERY-LOW-DENSITY LIPOPROTEINS. This disorder is due to mutation of APOLIPOPROTEINS E, a receptor-binding component of VLDL and CHYLOMICRONS, resulting in their reduced clearance and high plasma levels of both cholesterol and triglycerides.
An enzyme secreted from the liver into the plasma of many mammalian species. It catalyzes the esterification of the hydroxyl group of lipoprotein cholesterol by the transfer of a fatty acid from the C-2 position of lecithin. In familial lecithin:cholesterol acyltransferase deficiency disease, the absence of the enzyme results in an excess of unesterified cholesterol in plasma. EC 2.3.1.43.
Cholesterol which is contained in or bound to low density lipoproteins (LDL), including CHOLESTEROL ESTERS and free cholesterol.
Motifs in DNA- and RNA-binding proteins whose amino acids are folded into a single structural unit around a zinc atom. In the classic zinc finger, one zinc atom is bound to two cysteines and two histidines. In between the cysteines and histidines are 12 residues which form a DNA binding fingertip. By variations in the composition of the sequences in the fingertip and the number and spacing of tandem repeats of the motif, zinc fingers can form a large number of different sequence specific binding sites.
Enzymes which catalyze the hydrolases of ester bonds within DNA. EC 3.1.-.
Enzymes that catalyze the hydrolysis of the internal bonds and thereby the formation of polynucleotides or oligonucleotides from ribo- or deoxyribonucleotide chains. EC 3.1.-.
The integration of exogenous DNA into the genome of an organism at sites where its expression can be suitably controlled. This integration occurs as a result of homologous recombination.
A technique which uses synthetic oligonucleotides to direct the cell's inherent DNA repair system to correct a mutation at a specific site in an episome or chromosome.
A disease of pregnant and lactating cows and ewes leading to generalized paresis and death. The disease, which is characterized by hypocalcemia, occurs at or shortly after parturition in cows and within weeks before or after parturition in ewes.
Enzymes that catalyze the reversible reduction of alpha-carboxyl group of 3-hydroxy-3-methylglutaryl-coenzyme A to yield MEVALONIC ACID.
A condition of elevated levels of TRIGLYCERIDES in the blood.
A tree of the family Sterculiaceae (or Byttneriaceae), usually Theobroma cacao, or its seeds, which after fermentation and roasting, yield cocoa and chocolate.
Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process.
DNA sequences which are recognized (directly or indirectly) and bound by a DNA-dependent RNA polymerase during the initiation of transcription. Highly conserved sequences within the promoter include the Pribnow box in bacteria and the TATA BOX in eukaryotes.
The biosynthesis of RNA carried out on a template of DNA. The biosynthesis of DNA from an RNA template is called REVERSE TRANSCRIPTION.
An electrophoretic technique for assaying the binding of one compound to another. Typically one compound is labeled to follow its mobility during electrophoresis. If the labeled compound is bound by the other compound, then the mobility of the labeled compound through the electrophoretic medium will be retarded.
An antioxidant flavonoid, occurring especially in woody plants as both (+)-catechin and (-)-epicatechin (cis) forms.
C22-unsaturated fatty acids found predominantly in FISH OILS.
The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level.
A group of fatty acids, often of marine origin, which have the first unsaturated bond in the third position from the omega carbon. These fatty acids are believed to reduce serum triglycerides, prevent insulin resistance, improve lipid profile, prolong bleeding times, reduce platelet counts, and decrease platelet adhesiveness.
Organic, monobasic acids derived from hydrocarbons by the equivalent of oxidation of a methyl group to an alcohol, aldehyde, and then acid. Fatty acids are saturated and unsaturated (FATTY ACIDS, UNSATURATED). (Grant & Hackh's Chemical Dictionary, 5th ed)
Variant forms of the same gene, occupying the same locus on homologous CHROMOSOMES, and governing the variants in production of the same gene product.

Allele-specific differences in apolipoprotein C-III mRNA expression in human liver. (1/417)

BACKGROUND: Sequence variations at the apolipoprotein (apo)C-III gene locus have been associated with increased plasma triglycerides. In particular, the S2 allele of an SstI polymorphism in the 3' untranslated region has been associated with hypertriglyceridemia in many populations. The aim of this study was to determine whether the variant S2 allele is related to increased mRNA expression in vivo. METHODS: We measured allele-specific apoC-III expression in liver biopsies of five obese subjects, using restriction isotyping and a primer extension method, both based on the SstI polymorphism. RESULTS: The expression of mRNA by the S1 and S2 alleles was similar in two patients, whereas the mRNA encoded by the S2 allele was 14%, 26%, and 29% more abundant than the wild-type mRNA in the remaining three patients. Because other polymorphisms at the apoC-III gene locus have been implicated in the S2-associated hypertriglyceridemia, we determined apoC-III haplotypes comprising promoter polymorphisms at -935, -641, -630, -625, -482, -455, as well as the SstI sites and a BbvI site, both located in the 3' untranslated region. None of these polymorphisms nor any haplotype exhibited a perfect association with allele-specific expression, but variation at the T-482C site correlated in four of five subjects with the relative allele abundance. CONCLUSION: These data provide preliminary evidence for allele-specific differences in apoC-III mRNA expression in vivo and suggest that such differences may contribute to associations of apoC-III gene polymorphisms with hypertriglyceridemia.  (+info)

Vitamin A is linked to the expression of the AI-CIII-AIV gene cluster in familial combined hyperlipidemia. (2/417)

There is growing evidence of the capacity of vitamin A to regulate the expression of the genetic region that encodes apolipoproteins (apo) A-I, C-III, and A-IV. This region in turn has been proposed to modulate the expression of hyperlipidemia in the commonest genetic form of dyslipidemia, familial combined hyperlipidemia (FCHL). The hypothesis tested here was whether vitamin A (retinol), by controlling the expression of the AI-CIII-AIV gene cluster, plays a role in modulating the hyperlipidemic phenotype in FCHL. We approached the subject by studying three genetic variants of this region: a C1100-T transition in exon 3 of the apoC-III gene, a G3206-T transversion in exon 4 of the apoC-III gene, and a G-75-A substitution in the promoter region of the apoA-I gene. The association between plasma vitamin A concentrations and differences in the plasma concentrations of apolipoproteins A-I and C-III based on the different genotypes was assessed in 48 FCHL patients and 74 of their normolipidemic relatives. The results indicated that the subjects carrying genetic variants associated with increased concentrations of apoA-I and C-III (C1100-T and G-75-A) also presented increased plasma concentrations of vitamin A. This was only observed among the FCHL patients, which suggested that certain characteristics of these patients contributed to this association. The G3206-T was not associated with changes in either apolipoprotein concentrations or in vitamin A. In summary, we report a relationship between genetically determined elevations of proteins of the AI-CIII-AIV gene cluster and vitamin A in FCHL patients. More studies will be needed to confirm that vitamin A plays a role in FCHL which might also be important for its potential application to therapeutical approaches.  (+info)

Mass spectral study of polymorphism of the apolipoproteins of very low density lipoprotein. (3/417)

New isoforms of apolipoprotein (apo)C-I and apoC-III have been detected in delipidated fractions from very low density lipoprotein (VLDL) using matrix-assisted laser desorption (MALDI) and electrospray ionization (ESI) mass spectrometry (MS). The cleavage sites of truncated apoC-III isoforms have also been identified. The VLDL fractions were isolated by fixed-angle single-spin ultracentrifugation using a self-generating sucrose density gradient and delipidated using a newly developed C18 solid phase extraction protocol. Fifteen apoC isoforms and apoE were identified in the MALDI spectra and the existence of the more abundant species was verified by ESI-MS. The relative intensities of the apoCs are closely correlated in three normolipidemic subjects. A fourth subject with type V hyperlipidemia exhibited an elevated apoC-III level and a suppressed level of the newly discovered truncated apoC-I isoform. ApoC-II was found to be particularly sensitive to in vitro oxidation. The dynamic range and specificity of the MALDI assay shows that the complete apoC isoform profile and apoE phenotype can be obtained in a single measurement from the delipidated VLDL fraction.  (+info)

Kinetics and mechanism of exchange of apolipoprotein C-III molecules from very low density lipoprotein particles. (4/417)

Transfer of apolipoprotein (apo) molecules between lipoprotein particles is an important factor in modulating the metabolism of the particles. Although the phenomenon is well established, the kinetics and molecular mechanism of passive apo exchange/transfer have not been defined in detail. In this study, the kinetic parameters governing the movement of radiolabeled apoC molecules from human very low density lipoprotein (VLDL) to high density lipoprotein (HDL3) particles were measured using a manganese phosphate precipitation assay to rapidly separate the two types of lipoprotein particles. In the case of VLDL labeled with human [14C]apoCIII1, a large fraction of the apoCIII1 transfers to HDL3 within 1 minute of mixing the two lipoproteins at either 4 degrees or 37 degrees C. As the diameter of the VLDL donor particles is decreased from 42-59 to 23-25 nm, the size of this rapidly transferring apoCIII1 pool increases from about 50% to 85%. There is also a pool of apoCIII1 existing on the donor VLDL particles that transfers more slowly. This slow transfer follows a monoexponential rate equation; for 35-40 nm donor VLDL particles the pool size is approximately 20% and the t1/2 is approximately 3 h. The flux of apoCIII molecules between VLDL and HDL3 is bidirectional and all of the apoCIII seems to be available for exchange so that equilibrium is attained. It is likely that the two kinetic pools of apoCIII are related to conformational variations of individual apo molecules on the surface of VLDL particles. The rate of slow transfer of apoCIII1 from donor VLDL (35-40 nm) to acceptor HDL3 is unaffected by an increase in the acceptor to donor ratio, indicating that the transfer is not dependent on collisions between donor and acceptor particles. Consistent with this, apoCIII1 molecules can transfer from donor VLDL to acceptor HDL3 particles across a 50 kDa molecular mass cutoff semipermeable membrane separating the lipoprotein particles. These results indicate that apoC molecules transfer between VLDL and HDL3 particles by an aqueous diffusion mechanism.  (+info)

CREB-binding protein is a transcriptional coactivator for hepatocyte nuclear factor-4 and enhances apolipoprotein gene expression. (5/417)

Hepatocyte nuclear factor-4 (HNF-4) is a liver-enriched transcription factor that is crucial in the regulation of a large number of genes involved in glucose, cholesterol, and fatty acid metabolism and in determining the hepatic phenotype. We have previously shown that HNF-4 contains transcription activation functions at the N terminus (AF-1) and the C terminus (AF-2) which work synergistically to confer full HNF-4 activity. Here, we show that HNF-4 recruits the CREB-binding protein (CBP) coactivator on promoters of genes that contain functional HNF-4 sites. HNF-4 interacts with the N-terminal region of CBP (amino acids 1-771) and the C-terminal region of CBP (amino acids 1812-2441). The two activating functions of HNF-4, AF-1 and AF-2, interact with the N terminus and the N and C terminus of CBP, respectively. In addition, we show that in contrast to the other nuclear hormone receptors the interaction between HNF-4 and CBP is ligand-independent. Recruitment of CBP by HNF-4 results in an enhancement of the transcriptional activity of the latter. CBP does not activate gene expression in the absence of HNF-4, and dominant negative forms of HNF-4 prevent transcriptional activation by CBP, suggesting that the mere recruitment of CBP by HNF-4 is not sufficient for enhancement of gene expression. These findings demonstrate that CBP acts as a transcriptional coactivator for HNF-4 and provide new insights into the regulatory function of HNF-4.  (+info)

Characterization of remnant-like particles isolated by immunoaffinity gel from the plasma of type III and type IV hyperlipoproteinemic patients. (6/417)

Previous studies have investigated the potential atherogenicity and thrombogenicity of triglyceride-rich lipoprotein (TRL) remnants by isolating them from plasma within a remnant-like particle (RLP) fraction, using an immunoaffinity gel containing specific anti-apoB-100 and anti-apoA-I antibodies. In order to characterize lipoproteins in this RLP fraction and to determine to what extent their composition varies from one individual to another, we have used automated gel filtration chromatography to determine the size heterogeneity of RLP isolated from normolipidemic control subjects (n = 8), and from type III (n = 6) and type IV (n = 9) hyperlipoproteinemic patients, who by selection had similarly elevated levels of plasma triglyceride (406 +/- 43 and 397 +/- 35 mg/dl, respectively). Plasma RLP triglyceride, cholesterol, apoB, apoC-III, and apoE concentrations were elevated 2- to 6-fold (P < 0. 05) in hyperlipoproteinemic patients compared to controls. RLP fractions of type III patients were enriched in cholesterol and apoE compared to those of type IV patients, and RLP of type IV patients were enriched in triglyceride and apoC-III relative to those of normolipidemic subjects. In normolipidemic subjects, the majority of RLP had a size similar to LDL or HDL. The RLP of hyperlipoproteinemic patients were, however, larger and were similar in size to TRL, or were intermediate in size (i.e., ISL) between that of TRL and LDL. Compared to controls, ISL in the RLP fraction of type III patients were enriched in apoE relative to apoC-III, whereas in type IV patients they were enriched in apoC-III relative to apoE. These results demonstrate that: 1) RLP are heterogeneous in size and composition in both normolipidemic and hypertriglyceridemic subjects, and 2) the apoE and apoC-III composition of RLP is different in type III compared to type IV hyperlipoproteinemic patients.  (+info)

ApoCIII gene variants modulate postprandial response to both glucose and fat tolerance tests. (7/417)

BACKGROUND: We investigated the relationship between variation in the apolipoprotein (apo) AI-CIII-AIV gene cluster and response to an oral glucose test (OGTT) and oral fat load test (OFTT) in the EARSII group of young, healthy male offspring whose fathers had had a myocardial infarction before the age of 55 years (cases, n=407) compared with age-matched controls (n=415). The apoCIII variations examined were C3238G (SstI) in the 3'-UTR, C1100T in exon 3, C-482T in the insulin response element (IRE), and T-2854G in the apoCIII-AIV intergenic region. METHODS AND RESULTS: The postprandial response was regulated by variation at the T-2854G and C3238G sites. After the OFTT, carriers of the rare alleles had delayed clearance of triglyceride (Tg) levels; G-2854 carriers showed the largest effect on Tg (AUC, 24% greater, P<0.002; peak, 19% greater, P<0.005), and G3238 carriers showed a smaller response (AUC, 13% greater, P<0.05; peak, 13% greater, P=0.03). However, after adjustment for fasting level of Tg, only the effect with the T-2854G remained significant. Variation at the C-482T (IRE) determined response to the OGTT, with carriers of the rare T-482 having significantly elevated glucose (28.7% AUC, P=0.013) and insulin (20.5% AUC, P<0. 01) concentrations. CONCLUSIONS: These data suggest that specific genetic variants at the apoCIII gene locus differentially affect postprandial and response to OGTT and suggest a novel mechanism for the effects of variation at this locus on risk for atherosclerosis.  (+info)

Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis. (8/417)

BACKGROUND: The aim of this study was to establish whether there is a differential effect of mode of dialysis, hemodialysis (HD), or continuous ambulatory peritoneal dialysis (CAPD) on the dyslipidemia of renal failure. METHODS: The lipoprotein profile was determined in 61 non-diabetic patients on chronic HD (N = 30) and CAPD treatment (N = 31), and in a control group of 27 healthy subjects. The analysis included the measurement of individual apolipoprotein (apo) A- and apo B-containing lipoproteins (LPs) separated by sequential immunoaffinity chromatography. Apo A-containing lipoproteins include lipoprotein A-I with apo A-I and lipoprotein A-I:A-II with apo A-I and apo A-II as the main protein constituents, whereas apo B-containing lipoproteins comprise simple cholesterol-rich lipoprotein B (LP-B), with apo B as the only protein moiety and complex triglyceride (TG)-rich lipoprotein B complex (LP-Bc) particles with apo B, apo A-II, apo C, and/or apo E as the protein constituents. RESULTS: CAPD patients had significantly higher concentrations of total cholesterol (6.8 vs. 5.1 mmol/liter), low-density lipoprotein (LDL) cholesterol (4.6 vs. 3.2 mmol/liter), TG (2.3 vs. 1.5 mmol/liter), apo B (155.3 vs. 105.7 mg/dl), LP-B (136.0 vs. 91.9 mg/dl), and LP-Bc (19.3 vs. 13.8 mg/dl) than HD patients. Both HD and CAPD patients had significantly higher TG, VLDL cholesterol, apo C-III, and apo E and significantly lower high-density lipoprotein cholesterol, apo A-II, and lipoprotein A-I:A-II levels than control subjects. The distribution of apo C-III in high-density lipoprotein and VLDL-LDL was altered in CAPD patients in comparison with control subjects. This suggests that the removal of TG-rich lipoproteins is less efficient in patients on CAPD. Normotriglyceridemic (NTG; TG < or = 1.7 mmol/liter, 150 mg/dl) CAPD patients had significantly higher levels of TC, LDL cholesterol, apo B, and LP-B than NTG-HD patients. There was little difference in the LP-Bc levels between NTG-CAPD, NTG-HD, and controls. Similarly, hypertriglyceridemic (HTG) CAPD patients had significantly higher TC, LDL cholesterol, apo B, and LP-B levels than HTG-HD patients. The LP-Bc levels were significantly increased in HTG-HD and HTG-CAPD patients compared with controls, but the slightly higher levels in the CAPD patients did not differ significantly from the HD group. CONCLUSION: CAPD and HD patients have a lipoprotein profile characteristic of renal failure. Patients on long-term CAPD have higher levels of cholesterol-rich apo B-containing lipoproteins unrelated to TG levels. Many patients on CAPD also have a substantial elevation of the plasma concentrations of TG-rich LPs. The clinical significance of increased levels of potentially atherogenic LP-B during CAPD remains to be investigated.  (+info)

Apolipoprotein A-IV is a member of the apo A-I/C-III/A-IV gene cluster. In order to investigate its hypothetical coordinated regulation, an acute phase was induced in pigs by turpentine oil injection. The hepatic expression of the gene cluster as well as the plasma levels of apolipoproteins were monitored at different time periods. Furthermore, the involvement of the inflammatory mediators interleukins 1 and 6 and tumor necrosis factor in the regulation of this gene cluster was tested in cultured pig hepatocytes, incubated with those mediators and apo A-I/C-III/A-IV gene cluster expression at the mRNA level was measured. In response to turpentine oil-induced inflammation, a decreased hepatic apo A-IV mRNA expression was observed (independent of apo A-I and apo C-III mRNA) not correlating with the plasma protein levels. The distribution of plasma apo A-IV experienced a shift from HDL to larger particles. In contrast, the changes in apo A-I and apo C-III mRNA were reflected in their corresponding plasma
Apolipoprotein C-III, Human Plasma, Very Low-Density Lipoprotein Native Apolipoprotein C-III from human plasma found in VLDL and chylomicrons. Involved in triglyceride uptake by cells. Inhibits lipoprotein lipase and uptake of lipoprotein remnants by the liver. - Find MSDS or SDS, a COA, data sheets and more information.
Background: Apolipoprotein C-III (apoC-III) inhibits lipoprotein lipase activity and hepatic uptake of triglyceride-rich lipoproteins. Elevated levels of apoC-III have been found to be an independent predictor for CHD risk and genetically reduced apoC-III is associated with protection from CHD, making apoC-III a therapeutic target. Omega-3 fatty acid formulations containing docosahexaenoic acid (DHA) have been shown to increase LDL-C in patients with severe hypertriglyceridemia (HTG). Clinical data suggest that eicosapentaenoic acid (EPA) alone, which lowers triglycerides to a similar extent as EPA + DHA, does not raise LDL-C, but also fails to lower apoC-III. Materials: The EVOLVE trial evaluated 2, 3, and 4 g/d of a novel omega-3 free-fatty acid (FFA) formulation containing both EPA + DHA compared with 4 g/d of olive oil. In 399 patients with severe HTG we evaluated the effects on plasma apoC-III levels and the correlations between change in apoC-III and change in plasma lipids (TG, LDL-C) ...
We provide new information on the dose-ranging effect of rosuvastatin, a potent HMG-CoA (or 3-hydroxy-3-methyl-glutaryl-CoA) reductase inhibitor, on VLDL apoC-III metabolism in subjects with the metabolic syndrome. We demonstrated that rosuvastatin dose-dependently decreased VLDL apoC-III concentrations by increasing the FCR and decreasing the PR of VLDL apoC-III. These results add further to our work on the dose-dependent effect of rosuvastatin on apoB-containing lipoproteins and HDL particle kinetics in the same subjects (13,14).. Hypertriglyceridemia in insulin-resistant states, including the metabolic syndrome, results from overproduction and reduced catabolism of TRL and their remnants. These kinetic aberrations may be related to altered VLDL apoC-III metabolism. Previous studies demonstrated that overproduction of VLDL apoC-III explained the higher VLDL apoC-III concentration in these subjects (17). The increased VLDL apoC-III concentration and production rate were associated with elevated ...
Host Species: Goat Concentration: 1 mg/ml (OD 1.35 / 280 nm) Antigen: Human Apolipoprotein CIII Purification: Affinity purified Buffer: 75 mM Sodium Phosphate, 75 mM NaCl, 0.5 mM EDTA, 0.02% NaN3, pH 7.2 Specificity Specifically binds to human apo CIII. Dilution for immunoblot and ELISA range: 1,000 to 40,000. Use: The
Apolipoprotein CIII (apoCIII) is an independent risk for coronary heart disease (CHD). In this study, we investigated the associations among plasma apoCIII, hs-CRP and TNF-α levels and their roles in the clinical features of CHD in the Li and Han ethnic groups in China. A cohort of 474 participants was recruited (238 atherosclerotic patients and 236 healthy controls) from the Li and Han ethnic groups. Blood samples were obtained to evaluate apoCIII, TNF-α, hs-CRP and lipid profiles. Chi-squared, t-tests, and Kruskal-Wallis or Wilcoxon-Mann-Whitney tests, Pearson or Spearman correlation tests and multiple unconditional logistic regression were employed to analyze lipid profiles and variations in plasma apoCIII, TNF-α, hs-CRP in subgroups of CHD and their contributions to CHD using SPSS version 20.0 software. Compared to healthy participants, unfavorable lipid profiles were identified in CHD patients with enhanced systolic pressure, diastolic pressure, fasting blood sugar (FBS), TG, TC, LDL-C, apoB, Lp
UCL Discovery is UCLs open access repository, showcasing and providing access to UCL research outputs from all UCL disciplines.
RAPOSO, HELENA F.... Apolipoprotein CIII overexpression exacerbates diet-induced obesity due to adipose tissue higher exogenous lipid uptake and retention and lower lipolysis rates. NUTRITION & METABOLISM 12 n. p. DEC 23 2015. Journal article.
C H Bolton, A P Corfield, L G Downs; Sialidase Activity Acting on Apolipoprotein CIII 1 and 2 in Human Leukocytes and Platelets. Clin Sci (Lond) 1 January 1984; 67 (s9): 15P. doi: https://doi.org/10.1042/cs067015P. Download citation file:. ...
TY - JOUR. T1 - Diferencias según sexo y estado diabético en la relación entre apolipoproteína C-III y ácidos grasos libres con los triglicéridos séricos en sujetos a riesgo para intolerancia a la glucosa.. AU - Flórez, H.. AU - Méndez, A. J.. AU - Jones, L.. AU - Goldberg, R. B.. PY - 1999/3. Y1 - 1999/3. N2 - Insulin resistance and hyperinsulinemia can induce overproduction of triglyceride (TG) rich VLDL in the liver by increasing the availability of free fatty acids (FFA). Conversely, apolipoprotein C-III (apoC-III) is an inhibitor of the catabolism of TG-rich lipoproteins. To explore the relationship among FFA, apo C-III and TG in hyperinsulinemic subjects, we studied 103 individuals (63 women and 40 men) with a body mass index (BMI) 25 Kg/m2: 59 subjects with normal glucose tolerance (NGT), and 44 with newly diagnosed type 2 diabetes. After adjustment for age, BMI, fasting insulin and TG, FFA were significantly higher in women than in men and in subjects with diabetes compared with ...
Gotto, A.M.; Jackson, A.S.; Catapano, A.L.; Smith, L.C.; Paoletti, R.; Fruchart, J.C.; Clavey, V.; Luc, G.; Dallongeville, J.; Staels, B.; Auwerx, J.
Recent development in gene targeting tools makes production of knockout (KO) rabbits possible. In the present work, we generated five...
C2C12 myotubes exposed to VLDL showed increased levels of ER stress and inflammatory markers whereas peroxisome proliferator-activated receptor γ co-activator 1α (PGC-1α) and AMP-activated protein kinase (AMPK) levels were reduced and the insulin signalling pathway was attenuated. The effects of VLDL were also observed in isolated skeletal muscle incubated with VLDL. The changes caused by VLDL were dependent on extracellular signal-regulated kinase (ERK) 1/2 since they were prevented by the ERK1/2 inhibitor U0126 or by knockdown of this kinase by siRNA transfection. ApoCIII mimicked the effects of VLDL and its effects were also blocked by ERK1/2 inhibition, suggesting that this apolipoprotein was responsible for the effects of VLDL. Skeletal muscle from transgenic mice overexpressing apoCIII showed increased levels of some ER stress and inflammatory markers and increased phosphorylated ERK1/2 levels, whereas PGC-1α levels were reduced, confirming apoCIII effects in vivo. Finally, incubation ...
Results A higher triglyceride/cholesterol ratio of LDL was found more in HCV-infected donors than in healthy volunteers, and the triglyceride/cholesterol ratio of LDL-LVP was much increased, suggesting that the LPL hydrolysis of triglyceride may be impaired. VLDL, VLDL-LVP, LDL-LVP, but not LDL, suppressed LPL lipolytic activity, which was restored by antibodies that recognised apoC-III/-IV and correlated with the steadily abundant apoC-III/-IV quantities in those particles. In a cell-based system, treatment with VLDL and LVPs reversed the LPL-mediated inhibition of HCV infection in apoC-III/-IV-dependent manners. A multivariate logistic regression revealed that plasma HCV viral loads correlated negatively with LPL lipolytic activity, but positively with the apoC-III content of VLDL. Additionally, apoC-III in VLDL was associated with a higher proportion of HCV-RNA than was IgG.. ...
Jianglin Fan is the author of this article in the Journal of Visualized Experiments: Production of Apolipoprotein C-III Knockout Rabbits using Zinc Finger Nucleases
Isis Publishes Data Demonstrating Antisense Targeting of ApoC-III Significantly Reduces ApoC-III and Triglycerides Research Shows Antisense Inhibition of ApoC-III and Triglycerides in Multiple...
The authors of the following article have requested that it be retracted from publication in Circulation Research:. Kawakami A, Osaka M, Aikawa M, Uematsu S, Akira S, Libby P, Shimokado K, Sacks FM, Yoshida M. Toll-like receptor 2 mediates apolipoprotein CIII-induced monocyte activation. Circ Res. 2008;103:1402-1409.. The corresponding author, Dr Akio Kawakami, admitted to the editors to improperly handling the collection and presentation of data in this article such that the authors can no longer verify the authenticity and accuracy of the data presented. These errors include, but may not be limited to, the blots in Figure 2A, Figure 4D, and Online Figure III originating from unrelated experiments of the corresponding author, and the incorrect reporting of n in Figures 5 and 6, which are less than indicated. As such, data in those figures are not verifiable.. All co-authors involved in this study other than the corresponding author, Dr Kawakami, had no knowledge of any scientific impropriety ...
Rabbit polyclonal Apolipoprotein CIII antibody validated for WB, ELISA, ICC/IF, sELISA and tested in Human. Referenced in 3 publications. Immunogen…
Transcriptionally controlled transcription factor. Binds to DNA sites required for the transcription of alpha 1-antitrypsin, apolipoprotein CIII, transthyretin genes and HNF1-alpha. May be essential for development of the liver, kidney and intestine.
Ionis Pharmaceuticals, through its wholly owned subsidiary Akcea Therapeutics, is developing IONIS APOCIII LRx, a GalNAc3 conjugated antisense oligonucleotide
High-density lipoprotein (HDL) cholesterol is known as good cholesterol and can help ward off coronary heart disease (CHD). However, researchers have found that a subclass of HDL cholesterol can actually cause harm. A new study by the Harvard School of Public Health (HSPH) found that apolipoprotein C-III (apoC-III), a small protein that has been linked to HDL cholesterol can increase the risk of heart disease, but a lack of the protein can protect the heart.
Added to this, both observational and genetic studies have been concordant in showing that remnant cholesterol (which includes intermediate-density lipoproteins, very-low-density lipoproteins, and chylomicron remnants, the products of the lipolytic degradation of triglyceride-rich lipoproteins produced by the liver and intestine) is causal for ischaemic heart disease 8. Genetic studies have also shown associations between different players in triglyceride metabolism, apolipoprotein CIII and the angiopoietins-like 3 and 4 (ANGPTL3, ANGPTL4) and coronary artery disease (9-11); the latest Focus report discusses recent data for ANGPTL3 inhibition. Moreover, given the pivotal role of peroxisome proliferator-activated receptor ? (PPAR?) in controlling the expression of a number of key genes in triglyceride and HDL metabolism, efforts have been directed to modulating the unique receptor-cofactor binding profile to improve the potency and selectivity of PPAR? ligands (the SPPARM? concept). The ...
I didnt see a result the first week, shatavari health benefits but by the second week even my wife noticed the difference? Men of all ages may experience decrease in sexual ability, shatavari qualities but with OxySurge, you have an alternative to all the people who may dislike pills or capsules. If valve replacement is not possible, shatavari estrogen dominance long-term (possibly life-long) suppressive therapy with fluconazole may be used (C-III) [ 216, 228, 229]? De niet gefluoreerde hebben dat veel minder: 30-40 % is in een vrije vorm en is op die manier beschikbaar voor opname in die lichaamscellen waarin hun geneeskrachtige werking gezocht wordt. En duolin respules price sprightly quelle pharmacie acheter - dans lune des pharmacies en ville ou par Internet, cela sera votre choix, mais finalement vous allez obtenir des médicaments absolument identiques. Retin-A - Creme wirkt auf zweifache Weise, buy shatavari indem es die Verhornungsstörung behebt und die Haftung der Zellen vermindert, ...
WELCOME to the 103rd Season of the TOK-cok, SING-song, FOOD-Loving, BBB-spreading & Cat-Loving thread! Earlier threads - EXPOSE yourself - I EXPOSE yourself - II EXPOSE yourself - III EXPOSE yourself - IV EXPOSE yourself - V EXPOSE yourself - VI
WELCOME to the 103rd Season of the TOK-cok, SING-song, FOOD-Loving, BBB-spreading & Cat-Loving thread! Earlier threads - EXPOSE yourself - I EXPOSE yourself - II EXPOSE yourself - III EXPOSE yourself - IV EXPOSE yourself - V EXPOSE yourself - VI
Another substance class on the rise in cardiovascular medicine are so-called anti-sense oligonucleotides, single strands of DNA or RNA binding complementary to a chosen mRNA sequence, thereby preventing protein translation. Besides a fascinating novel anti-coagulatory approach by inhibiting coagulation factor XI production, the biggest focus of this novel therapeutic approach lies on lipidology. Within this review we will highlight the current evidence on antisense therapy against apolipoprotein B, apolipoprotein A as well as apolipoprotein CIII, that are in very different stages of development, however, with some exciting early data.. Kurzfassung: Biologika begr nden eine neue Medikamentenklasse, werden biotechnologisch hergestellt und greifen gezielt in molekularbiologische Mechanismen ein. Lange Zeit eine Dom ne der H matologie, Onkologie sowie der Rheumatologie, treten monoklonale Antik rper als Therapeutika nun auch langsam in der Kardiologie ihren Siegeszug an. Neben dem schon seit mehr ...
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details ...
T rk yeti kinlerinde koroner kalp hastal (KKH) morbidite ve mortalitesinin di er toplumlardan farkl bi imde y ksek oldu una ili kin TEKHARF al mas bilgisi, yak n zamanda daha g l bi imde do rulanm t r. Bu derlemede, an lan g zlemin alt nda yatan kandaki koruyucu proteinlerin i levlerini yitirmesinin, hatta proenflamatuvar ve aterojen niteliklere b r nmesi olay n n, toplumumuzda metabolik sendrom (MetS) yayg nl na e lik eden dislipidemi, oksidatif s re ve sistemik yang sonucuna ba lanabilece i zerinde duruldu. Koruyucu i levlerinde bozukluk g zlemlenen proteinler y ksek yo unluklu lipoprotein (HDL) par ac klar ile, bunun zerinde yer alan apolipoprotein (apo) A-I, A-II ve C-III, ayr ca, adiponektin olup d nyada ilk kez genel n fusta tarif edilmektedir. MetS, tip 2 diyabet ve KKH den olu an kardiyometabolik riskte, kanda C-reaktif protein (CRP), apoB, apoC-III, fibrinojen y ksekli i ve adiponektin d kl gibi yang g stergelerinin rol , bunlar n MetS e dair ATP-III tan m ndan ba ms zl k oran ve bunda ...
hazard ratio per 1 SD [HR/SD]: 1.40; 95% confidence interval [CI]: 1.17 to 1.67), apoC-III (HR/SD: 1.38; 95% CI: 1.17 to 1.63), and apoE (HR/SD: 1.31; 95% CI: 1.13 to 1.52). Associations were independent of high-density lipoprotein ...
View Ldlr/Ldlr Tg(APOC3)3707Bres/? involves: 129S7/SvEvBrd * C57BL/6J * CBA/J: phenotypes, images, diseases, and references.
Compare APOC1 ELISA Kits from Biorbyt from leading suppliers on Biocompare. View specifications, prices, citations, reviews, and more.
Apolipoprotein C-II deficiency (APOC2) Test Cost INR 30000.00 Surat Pune Jaipur Lucknow Kanpur Nagpur Visakhapatnam Indore Thane Bhopal Patna Vadodara Ghaziabad Ludhiana Coimbatore Madurai Meerut Ranchi Allahabad Trivandrum Pondicherry Mysore Aligarh best offer discount price
Distribution of apolipoprotein C-II mRNA and protein in the perinatal mouse lung. Mouse tissue sections are from saccular stage (A, B, H, GD 19.5; C, G, PN 0; I
Serum: Use a serum separator tube (SST) and allow samples to clot for two hours at room temperature or overnight at 4°C before centrifugation for 15 minutes at 1000 ×g. Remove serum and assay immediately or aliquot and store samples at -20°C or -80°C. Avoid repeated freeze-thaw cycles ...
Gentaur molecular products has all kinds of products like :search , Alpha Dia \ Anti_Human Plasma Apolipoprotein A_I protein antiserum \ APOA11-S for more molecular products just contact us
UCL Discovery is UCLs open access repository, showcasing and providing access to UCL research outputs from all UCL disciplines.
Apolipoprotein A-IV/ApoA4 Antibody Pair. Matched antibody pairs validated for ELISA or IP-Western Blot. Backed by our 100% Guarantee.
MAPLE GROVE, Minn., Aug. 16, 2013 /PRNewswire/ -- Upsher-Smith Receives Tentative NDA Approval for Vogelxo™ (testosterone) Gel CIII.
APOC4 Antibody 16530-1-AP has been identified with IF, WB, ELISA. 16530-1-AP detected 17 kDa band in human plasma tissue with 1:200-1:1000 dilution...
Apolipoprotein C2 or apolipoprotein C-II is a protein that in humans is encoded by the APOC2 gene. secreted in plasma where it is a component of very low density lipoproteins and chylomicrons. This protein activates the enzyme lipoprotein lipase in capillaries,[5] which hydrolyzes triglycerides and thus provides free fatty acids for cells. Mutations in this gene cause hyperlipoproteinemia type IB, characterized by xanthomas, pancreatitis, and hepatosplenomegaly, but no increased risk for atherosclerosis. Lab tests will show elevated blood levels of triglycerides, cholesterol, and chylomicrons[6] ...
Apolipoproteins function as structural components of lipoprotein particles, cofactors for enzymes, and ligands for cell-surface receptors. Most of the apoliporoteins exhibit proteoforms, arising from single nucleotide polymorphisms (SNPs) and post-translational modifications such as glycosylation, oxidation, and sequence truncations. Reviewed here are recent studies correlating apolipoproteins proteoforms with the specific clinical measures of lipid metabolism and cardiometabolic risk. Targeted mass spectrometric immunoassays toward apolipoproteins A-I, A-II, and C-III were applied on large cross-sectional and longitudinal clinical cohorts. Several correlations were observed, including greater apolipoprotein A-I and A-II oxidation in patients with diabetes and cardiovascular disease, and a divergent apoC-III proteoforms association with plasma triglycerides, indicating significant differences in the metabolism of the individual apoC-III proteoforms. These are the first studies of their kind, correlating
66 products from 17 suppliers. Compare and order APOC1 ELISA Kits. View citations, images, detection ranges, sensitivity, prices and more. Recommended products for the most popular species. Our scientists will help you find the right ELISA kit for your needs.
Mar 7, 2005. rich lipoproteins secreted from doxycycline-treated cells was larger. cept that these two key apolipoproteins may interact within the
EDWIN.LEE LWCOLX, aged 20 months, son loss I of only 12 or 15. Sorghum; -Feed has i tctlliIJUlIIlnIlClrllillo 1Ifurim.l. Brrnnr: /: l-anl>-I.!, Clerk;tl Circuit l nloIIIII..IIII1CIII.Court. I t.t l 1-e ili clf! ,,theharjuil estate thertfrtun.\\iIIiull!: Carlton duvJ: and ask HEIIERY: notiHe the public that he has \l t.1.L- twenty execute years in. EuroiHt: : and j practiced America.the lie tradi engagfor :.- ,J ...
Apolipoprotein (apolipoprotein) je bílkovinná složka lipoproteinů. Apolipoproteinů existuje více druhů a jednotlivé typy se vyskytují v konkrétních lipoproteinech. Apolipoproteiny mají více funkcí, jsou strukturálně důležité, pomáhají transportu lipoproteinových částic, a dokonce mohou fungovat jako koenzymy některých enzymů ...
article: Hypertriglyceridemic pancreatitis - Minerva Gastroenterologica e Dietologica 2020 September;66(3):238-45 - Minerva Medica - Journals
Aim: There remains high unmet medical need for therapies to treat cardio/metabolic diseases. We validated in human trials, a platform for reducing the synthesis of genes expressed in the liver. The platform utilizes a GalNAc ligand attached to the 3 end of the sense strand of an RNAi molecule to enable delivery specifically to the liver. Here we extend the platform to targets of interest in cardiovascular disease, including PCSK9, ANGPLT3 and ApoC3.. METHODS: Chemically modified siRNAs were designed and were screened for potency in vitro. pM active siRNA molecules were developed targeting PCSK9, ANGPLT3 and ApoC3. The siRNAs were tested in either rodents or in non-human primates (NHPs) for activity.. RESULTS: In NHPs a single dose of ALN-PCSsc at 6 mg/kg reduced PCSK9 levels up to 97% and LDL-C up to 67%. Moreover the nadir effect (without any rebound of LDL-C) lasted ,30 days indicating that once a month or longer dosing frequency in clinic should be supported. Multidose studies in NHP at ...
Read Chapter CIII of Of Human Bondage by William Somerset Maugham. The text begins: Mrs. Athelny lent Philip money to pay his landlady enough of her bill to let him take his things away. For five shillings and the pawn-ticket on a suit he was able to get from a pawnbroker a frock coat which fitted him fairly well. He redeemed the rest of his clothes. He sent his box to Harrington Street by Carter Patterson and on Monday morning went with Athelny to the shop. Athelny introduced him to the buyer of the costumes and left him. The buyer was a pleasant, fussy little man of thirty, named Sampson; he shook hands with Philip, and, in order to show his own accomplishment of which he was very proud, asked him if ...
Nachschlagewerk für Laborärzte, Medizinisch-technische Assistenten, Einkäufer in Krankenhäusern, Medizinstudenten und angehende MTAs. Die Website bietet einen unabhängigen Marktüberblick über Produkte vom Blutzuckermessgerät bis zum Großanalyser, vom Autoklaven bis zur Zentrifuge. Seite: Apolipoprotein B
Hypertriglyceridemia occurs when there are too many triglycerides, which are a type of fatty molecule, in the blood. This can be associated with hardening of the arteries and inflammation of the pancreatitis. Talk to a cardiologist about lowering your triglyceride levels in Kalamazoo, MI.
Too high of triglyceride levels, or hypertriglyceridemia, leads to increased risks of heart disease, stroke and fatty liver, among others.
Iorovi Medica Bucuresti - Laborator analize medicale - Bucuresti | , Laborator de analize, Anatomie patologica, Genetica medicala, Laborator de analize medicale complete
Use Bio-Rads PrimePCR assays, controls, templates for your target gene. Every primer pair is optimized, experimentally validated, and performance guaranteed.
Use Bio-Rads PrimePCR assays, controls, templates for your target gene. Every primer pair is optimized, experimentally validated, and performance guaranteed.
Yunifiar M, Muhammad Qushai; Kotaki, Tomohiro; Witaningrum, Adiana Mutamsari; Khairunisa, Siti Qamariyah; Indriati, Dwi Wahyu; Meilani, Meilani; Yeheskiel, Tigor; Ueda, Shuhei; Nasronudin, Nasronudin; Kameoka, ...
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok ...
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Accept ...
Yunifiar M, Muhammad Qushai; Kotaki, Tomohiro; Witaningrum, Adiana Mutamsari; Khairunisa, Siti Qamariyah; Indriati, Dwi Wahyu; Meilani, Meilani; Yeheskiel, Tigor; Ueda, Shuhei; Nasronudin, Nasronudin; Kameoka, ...
Fornire salute visiva, attraverso unassistenza medica e diagnostica al massimo livello, con costante attenzione allaspetto umano e alle necessità di ogni singolo Paziente.
Apolipoprotein A-II is a protein that in humans is encoded by the APOA2 gene. This gene encodes apolipoprotein (apo-) A-II, ... "Entrez Gene: APOA2 apolipoprotein A-II". Pussinen PJ, Jauhiainen M, Metso J, Pyle LE, Marcel YL, Fidge NH, Ehnholm C (Jan 1998 ... Brewer HB, Lux SE, Ronan R, John KM (May 1972). "Amino acid sequence of human apoLp-Gln-II (apoA-II), an apolipoprotein ... The protein is found in plasma as a monomer, homodimer, or heterodimer with apolipoprotein D. Defects in this gene may result ...
Apolipoprotein L3 is a protein that in humans is encoded by the APOL3 gene. This gene is a member of the apolipoprotein L gene ... Six transcript variants encoding three different isoforms have been found for this gene. GRCh38: Ensembl release 89: ... "Entrez Gene: APOL3 apolipoprotein L, 3". Human APOL3 genome location and APOL3 gene details page in the UCSC Genome Browser. ... 2001). "Apolipoprotein L gene family: tissue-specific expression, splicing, promoter regions; discovery of a new gene". J. ...
Apolipoprotein L2 is a protein that in humans is encoded by the APOL2 gene. This gene is a member of the apolipoprotein L gene ... "Entrez Gene: APOL2 apolipoprotein L, 2". "The Human Protein atlas Gene: APOL2 apolipoprotein L, 2". Liao W, Goh FY, Betts RJ, ... "Nextprot Gene: APOL2 apolipoprotein L, 2". Human APOL2 genome location and APOL2 gene details page in the UCSC Genome Browser. ... "The Human Protein atlas Gene: APOL2 apolipoprotein L, 2". Rao SK, Pavicevic Z, Du Z, Kim JG, Fan M, Jiao Y, Rosebush M, Samant ...
Apolipoprotein L6 is a protein that in humans is encoded by the APOL6 gene. This gene is a member of the apolipoprotein L gene ... "Entrez Gene: APOL6 apolipoprotein L, 6". Human APOL6 genome location and APOL6 gene details page in the UCSC Genome Browser. ... Liu Z, Lu H, Jiang Z, Pastuszyn A, Hu CA (Jan 2005). "Apolipoprotein l6, a novel proapoptotic Bcl-2 homology 3-only protein, ... Page NM, Butlin DJ, Lomthaisong K, Lowry PJ (May 2001). "The human apolipoprotein L gene cluster: identification, ...
Kim DH, Iijima H, Goto K, Sakai J, Ishii H, Kim HJ, Suzuki H, Kondo H, Saeki S, Yamamoto T (Jun 1996). "Human apolipoprotein E ... It is separated into a ligand binding domain of eight ligand binding regions, an EGF-like domain containing three cysteine-rich ... Apolipoprotein E (ApoE) plays an important role in phospholipid and cholesterol homeostasis. After binding ApoER2, ApoE is ... Riddell DR, Sun XM, Stannard AK, Soutar AK, Owen JS (2001). "Localization of apolipoprotein E receptor 2 to caveolae in the ...
Sacks FM, Zheng C, Cohn JS (2011). "Complexities of plasma apolipoprotein C-III metabolism". Journal of Lipid Research. 52 (6 ... Adult Treatment Panel III Full Report - National Heart, Lung, and Blood Institute ATP III Update 2004 - National Heart, Lung, ... Its most abundant apolipoproteins are apo A-I and apo A-II.[citation needed] A rare genetic variant, ApoA-1 Milano, has been ... In the stress response, serum amyloid A, which is one of the acute-phase proteins and an apolipoprotein, is under the ...
Thus one extra sialyl residue on apolipoprotein C3 impairs its action on lipoprotein lipase. This can affect expression of the ... apolipoprotein C3 and atherosclerosis". Current Opinion in Lipidology. 28 (4): 308-312. doi:10.1097/MOL.0000000000000425. PMID ... "An abnormal triglyceride-rich lipoprotein containing excess sialylated apolipoprotein". Journal of Clinical Investigation. 69 ( ... "Hypertriglyceridaemia associated with an abnormal triglyceride-rich lipoprotein carrying excess apolipoprotein". Lancet. 2: 667 ...
... peptides such as adrenomedullin and apolipoprotein; and iii) hemin. NRF2 inducers with downstream HO-1 induction include: ... The reaction comprises three steps, which may be: Heme b3+ + O 2 + NADPH + H+ → α-meso-hydroxyheme3+ + NADP+ + H 2O α-meso- ... In humans three isoforms of heme oxygenase are known. Heme oxygenase 1 (HO-1) is a stress-induced isoform present throughout ... ISBN 978-3-319-06150-4. Ma Q, He X (2012). "Molecular basis of electrophilic and oxidative defense: promises and perils of Nrf2 ...
The basics of MR were invented by Martijn B. Katan in 1986, when he suggested the use of apolipoprotein E alleles, that had ... Katan MB (March 1986). "Apolipoprotein E isoforms, serum cholesterol, and cancer". Lancet. 1 (8479): 507-8. doi:10.1016/s0140- ... 288 (3): 321-33. doi:10.1001/jama.288.3.321. PMID 12117397. Fisher, R.A. (April 2010). "Statistical methods in genetics 1951". ... 7 Suppl 3: 9-12. PMID 1855097. Davey Smith, G. (September 2010). "Mendelian Randomization for Strengthening Causal Inference in ...
August 1992). "Apolipoprotein AI mutation Arg-60 causes autosomal dominant amyloidosis". Proc. Natl. Acad. Sci. U.S.A. 89 (16 ... with congenital mutations in apolipoprotein A1 and lysozyme. It is also known as "Ostertag" type, after B. Ostertag, who ... 118 (3): 321-2. doi:10.1016/j.amjmed.2004.10.022. PMID 15745733. Granel B, Valleix S, Serratrice J, et al. (January 2006). " ... 5 (3): 188-92. doi:10.3109/13506129809003844. PMID 9818055. Soutar AK, Hawkins PN, Vigushin DM, et al. ( ...
Class III: LDLR does not properly bind LDL on the cell surface because of a defect in either apolipoprotein B100 (R3500Q) or in ... Apolipoprotein B, in its ApoB100 form, is the main apolipoprotein, or protein part of the lipoprotein particle. Its gene is ... In January 2013, The US FDA also approved mipomersen, which inhibits the action of the gene apolipoprotein B, for the treatment ... LDL cholesterol normally circulates in the body for 2.5 days, and subsequently the apolipoprotein B portion of LDL cholesterol ...
Apolipoprotein B mRNA editing enzyme, catalytic polypeptide 1 also known as C->U-editing enzyme APOBEC-1 is a protein that in ... The structure of A1 relies on three dimensional folds induced by a zinc complex. These folds allow the enzyme to access the RNA ... "Entrez Gene: APOBEC1 apolipoprotein B mRNA editing enzyme, catalytic polypeptide 1". Rosenberg BR, Hamilton CE, Mwangi MM, ... Lau PP, Zhu HJ, Nakamuta M, Chan L (1997). "Cloning of an Apobec-1-binding protein that also interacts with apolipoprotein B ...
"Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia". The New England Journal of Medicine. 373 ( ... 62 (3): 489-95. doi:10.1016/j.jaad.2009.04.046. PMID 20159315. Polyzos SA, Perakakis N, Mantzoros CS (2019). "Fatty liver in ...
... although nonglycosylated and immature forms of apolipoprotein[a] are competent to associate with apolipoprotein B-100 in vitro ... The half-life of Lp(a) in circulation is approximately three to four days. The mechanism and sites of Lp(a) catabolism are ... The structure of apolipoprotein(a) is similar to plasminogen and tPA (tissue plasminogen activator) and it competes with ... III. Contribution of Lp(a) glycoprotein phenotypes to normal lipid variation". Hum. Genet. 82 (1): 73-8. doi:10.1007/BF00288277 ...
Apolipoprotein B48 on chylomicra and Apolipoprotein B100 on LDL, IDL, and VLDL are important for MTP binding. Click on genes, ... Gordon DA (1997). "Recent advances in elucidating the role of the microsomal triaglyceride transfer protein in apolipoprotein B ... 1999). "A common binding site on the microsomal triaglyceride transfer protein for apolipoprotein B and protein disulfide ... The network of endoplasmic reticulum-resident chaperones (ERp72, GRP94, calreticulin, and BiP) interacts with apolipoprotein b ...
Also, a specific isoform of apolipoprotein, APOE4, is a major genetic risk factor for AD. While apolipoproteins enhance the ... The three stages are described as early or mild, middle or moderate, and late or severe. The disease is known to target the ... The APOEε4 allele increases the risk of the disease by three times in heterozygotes and by 15 times in homozygotes. Like many ... APOEε4 is one of four alleles of apolipoprotein E (APOE). APOE plays a major role in lipid-binding proteins in lipoprotein ...
Basu SK, Goldstein JL, Brown MS (Feb 1983). "Independent pathways for secretion of cholesterol and apolipoprotein E by ... 89 (3): 331-40. doi:10.1016/S0092-8674(00)80213-5. PMID 9150132. S2CID 17882616. DeBose-Boyd RA, Brown MS, Li WP, Nohturfft A, ... 65 (3): 429-34. doi:10.1016/0092-8674(91)90460-G. PMID 2018975. S2CID 54388220. Chen WJ, Andres DA, Goldstein JL, Russell DW, ... 102 (3): 315-23. doi:10.1016/S0092-8674(00)00037-4. PMID 10975522. S2CID 18054832. Yang T, Espenshade PJ, Wright ME, et al. ( ...
All members of this family are receptors for Apolipoprotein E (ApoE). Therefore, they are often synonymously referred to as ' ... This fragment may serve postnatally to prevent apical dendrites of cortical layer II/III pyramidal neurons from overgrowth, ... Andersen OM, Benhayon D, Curran T, Willnow TE (August 2003). "Differential binding of ligands to the apolipoprotein E receptor ... Herz J, Beffert U (October 2000). "Apolipoprotein E receptors: linking brain development and Alzheimer's disease". Nature ...
Takahashi K, Ikeo K, Gojobori T (1991). "Evolutionary origin of numerous kringles in human and simian apolipoprotein(a)". FEBS ... Kringle domains have been found in plasminogen, hepatocyte growth factors, prothrombin, and apolipoprotein(a). Kringles are ... 212 (3): 541-552. doi:10.1016/0022-2836(90)90330-O. PMID 2157850. Castellino FJ, Beals JM (1987). "The genetic relationships ... Kringle domains are characterised by a triple loop, 3-disulfide bridge structure, whose conformation is defined by a number of ...
... and involves apolipoprotein A1. "FAP-IV" is also known as "Finnish-type", and involves gelsolin. Fibrinogen, apolipoprotein A1 ... Senile systemic amyloidosis [abbreviated "SSA"] is also associated with transthyretin aggregation.) "FAP-III" is also known as ... These proteins include: transthyretin (ATTR, the most commonly implicated protein), apolipoprotein A1, and gelsolin. Due to the ... 11 (3): 185-6. doi:10.1038/nrd3675. PMID 22378262. Grogan, Kevin (19 June 2012). "FDA rejects Pfizer rare disease drug ...
"Deficiency of glycine N-methyltransferase aggravates atherosclerosis in apolipoprotein E-null mice". Molecular Medicine. 18 (5 ... 87: 132-3. doi:10.1016/j.jprot.2013.01.007. PMID 23340451. Chen CY, Ching LC, Liao YJ, Yu YB, Tsou CY, Shyue SK, Chen YM, Lee ... 235 (3): 296-304. doi:10.1016/j.taap.2008.12.013. PMID 19146867. Chen YM, Shiu JY, Tzeng SJ, Shih LS, Chen YJ, Lui WY, Chen PH ... 18 (3): 412-22. doi:10.2119/molmed.2011.00258. PMC 3356423. PMID 22183894. Chen M, Ho CW, Huang YC, Wu KY, Wu MT, Jeng HA, Chen ...
"Entrez Gene: APOBEC3C apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3C". Yu Q, Chen D, König R, Mariani R, ... 457 (3): 295-9. doi:10.1016/j.bbrc.2014.12.103. hdl:2297/44628. PMID 25576866. Yu Q, König R, Pillai S, Chiles K, Kearney M, ... 8 (3): 148-57. PMID 17078485. Madsen P, Anant S, Rasmussen HH, Gromov P, Vorum H, Dumanski JP, Tommerup N, Collins JE, Wright ... 94 (1-3): 203-8. doi:10.1016/j.jsbmb.2005.01.007. PMID 15862967. Doehle BP, Schäfer A, Wiegand HL, Bogerd HP, Cullen BR (July ...
Ichinose A (1992). "Multiple members of the plasminogen-apolipoprotein(a) gene family associated with thrombosis". Biochemistry ... 4 (3): 449-51. doi:10.1016/0888-7543(89)90356-X. PMID 2714803. Magnaghi P, Citterio E, Malgaretti N, et al. (1994). "Molecular ... 3 (3): 437-42. doi:10.1093/hmg/3.3.437. PMID 8012354. Kida M, Wakabayashi S, Ichinose A (1997). "Characterization of the 5'- ... 259 (3): 618-25. doi:10.1046/j.1432-1327.1999.00055.x. PMID 10092845. Strausberg RL, Feingold EA, Grouse LH, et al. (2003). " ...
It contains three exons that span more than 5 kb of genomic DNA, and it encodes a fucosyltransferase that produces the H ... Apolipoprotein E, gene associated with Alzheimer's disease. Gene map locus 19q13.2 CIC: Capicua transcriptional repressor. Gene ... 64 (3): 189-196. doi:10.1046/j.1469-1809.2000.6430189.x. PMC 3376086. PMID 11409409. Dean, L. (2005). "Ch. 5: The ABO blood ... ISBN 978-3-318-02253-7. Sethakulvichai, W.; Manitpornsut, S.; Wiboonrat, M.; Lilakiatsakun, W.; Assawamakin, A.; Tongsima, S. ( ...
April 1987). "Association of an apolipoprotein CII allele with familial dementia of the Alzheimer type". Journal of ... 4 (2-3): 97-108. doi:10.3109/01677068709102337. PMID 2885403. Martin GM (1971). "Brief proposal on immortality: an interim ...
"The antioxidant N-acetylcysteine prevents accelerated atherosclerosis in uremic apolipoprotein E knockout mice". Kidney ... 50 (3): 341-51. doi:10.1177/002215540205000306. PMID 11850437. Pacher P, Obrosova IG, Mabley JG, Szabó C (2005). "Role of ... 12 (3): 267-75. doi:10.2174/0929867053363207. PMC 2225483. PMID 15723618. Ivanovski O, Szumilak D, Nguyen-Khoa T, Ruellan N, ... 3-Nitro-L-tyrosine at Sigma-Aldrich Ischiropoulos H (August 1998). "Biological tyrosine nitration: a pathophysiological ...
Christenson LK, Strauss III JF (2001). "Steroidogenic acute regulatory protein: an update on its regulation and mechanism of ... "Overexpression of steroidogenic acute regulatory protein increases macrophage cholesterol efflux to apolipoprotein AI". ... Lin D, Sugawara T, Strauss III JF, Clark BJ, Stocco DM, Saenger P, Rogol A, Miller WL (March 1995). "Role of steroidogenic ... Steroidogenic enzyme Kallen CB, Billheimer JT, Summers SA, Stayrook SE, Lewis M, Strauss III JF (October 1998). "Steroidogenic ...
Apolipoprotein M is a protein that in humans is encoded by the APOM gene. The protein encoded by this gene is an apolipoprotein ... 2004). "Analysis of the Gene-Dense Major Histocompatibility Complex Class III Region and Its Comparison to Mouse". Genome Res. ... "Entrez Gene: APOM apolipoprotein M". Albertella MR, Jones H, Thomson W, et al. (1997). "Localization of eight additional genes ... Overview of all the structural information available in the PDB for UniProt: O95445 (Human Apolipoprotein M) at the PDBe-KB. v ...
Three types of DCs have been defined in human blood: the CD1c+ myeloid DCs, the CD141+ myeloid DCs and the CD303+ plasmacytoid ... Monocytes can be induced to differentiate into dendritic cells by a self-peptide Ep1.B derived from apolipoprotein E. These are ... In the lymph node and secondary lymphoid organs, all three cell types can activate naive T cells. Whereas mature dendritic ... For this activation of dendritic cells, concurrent interaction of all three cell types, namely CD4+ T helper cells, CD8+ T ...
Cholesterol is imported into the neuron by apolipoprotein E (apoE) via LRP1 receptors on the cell surface. It has been ... Low density lipoprotein receptor-related protein 1 (LRP1), also known as alpha-2-macroglobulin receptor (A2MR), apolipoprotein ... "Apolipoprotein E isoform-specific effects on lipoprotein receptor processing". Neuromolecular Medicine. 16 (4): 686-696. doi: ... "Interaction of cytosolic adaptor proteins with neuronal apolipoprotein E receptors and the amyloid precursor protein". The ...
Text is available under the Creative Commons Attribution-ShareAlike License; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization ...
Apolipoprotein C-IV, also known as apolipoprotein C4, is a protein that in humans is encoded by the APOC4 gene.[5][6] ... Apolipoprotein (apo)C4 gene is a member of the apolipoprotein C gene family. It is expressed in the liver and has a predicted ... "Entrez Gene: apolipoprotein C-IV".. *^ Allan CM, Walker D, Segrest JP, Taylor JM (July 1995). "Identification and ... 2002). "Regulated expression of the apolipoprotein E/C-I/C-IV/C-II gene cluster in murine and human macrophages. A critical ...
Aktivin i inhibin • ADAM • Alfa 1-antihimotripsin • Apolipoprotein H • CD70 • Asijaloglikoprotein • Avidin • B-ćelijski ... Biol. 65 (5): 680-3. PMID 10331498. Cite uses deprecated parameter ,month=. (help) ... 1999). "BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator.". Science 285 (5425): 260-3. PMID ... Za njega je bilo pokazano da igra važnu ulogu u proliferaciji i diferencijaciji B ćelija.[3] ...
2008, 2 (1): I-II. PMID 24351678. doi:10.1016/j.orcp.2008.01.001.. ... 載脂蛋白B缺乏症(英语:Apolipoprotein B deficiency) ... 具有FTO基因的人若定期進行中等强度体力活动(相当于3-4小时的快步行走)时,罹患肥胖的機率就會下降[122]。有一个研究表明 ... 低热量饮食:指每天只摄入800-1500kcal热量,形成能量负平衡,
... adjusted for apolipoprotein A-I and apolipoprotein B) and increased risk of cardiovascular disease, casting doubt on the ... "Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report" (PDF). ... By serving as ligands for specific receptors on cell membranes, the apolipoproteins that reside on the surface of a given ... van der Steeg WA (2008). "High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I ...
primary: Antithrombin III deficiency. *Protein C deficiency/Activated protein C resistance/Protein S deficiency/Factor V Leiden ... a) Vascular thrombosis in three or more organs or tissues and. *b) Development of manifestations simultaneously or in less than ... and two antibody blood tests spaced at least three months apart that confirm the presence of either lupus anticoagulant or anti ... 59 (3): 635-46. PMID 10029789.. *^ de Jong PG, Goddijn M, Middeldorp S (2013). "Antithrombotic therapy for pregnancy loss". ...
Class III: LDLR does not properly bind LDL on the cell surface because of a defect in either apolipoprotein B100 (R3500Q) or in ... Apolipoprotein BEdit. Apolipoprotein B, in its ApoB100 form, is the main apolipoprotein, or protein part of the lipoprotein ... LDL cholesterol normally circulates in the body for 2.5 days, and subsequently the apolipoprotein B portion of LDL cholesterol ... or apolipoprotein B (ApoB), which is the part of LDL that binds with the receptor; mutations in other genes are rare.[1] People ...
APOA4: apolipoprotein A-IV. *ATM: ataxia telangiectasia mutated (includes complementation groups A, C and D) ...
The term epigenetics refers to three levels of gene regulation: (1) DNA methylation, (2) histone modifications, and (3) non- ... and familial inheritance of apolipoprotein E allele epsilon 4. In addition to these common factors, there are a number of other ... Class I and II HDAC inhibitors such as trichostatin A, vorinostat, and sodium butyrate, and Class III HDACis, such as ... Weihl CC, Connolly AM, Pestronk A (August 2006). "Valproate may improve strength and function in patients with type III/IV ...
A three-year National Institutes of Health trial in people with mild cognitive impairment reported donepezil was superior to ... a subgroup of individuals with the apolipoprotein E4 genotype showed sustained benefits with donepezil throughout the study.[34 ... Side effects are mild and transient in most patients, lasting up to three weeks and usually improved even with continued use.[ ... 70 hours[3] Around 100 hours in elderly patients.[1]. Duration of action. With daily dosing, steady-state concentration is ...
The La antigen is a 48kDa transcription termination factor of RNA polymerase III, which associates with the Ro-RNP complex.[15] ... 25 (3): 480-6. PMC 1541410. PMID 786521.. *^ Shapiro, TA; Englund, PT (1995). "The structure and replication of kinetoplast DNA ... 15 (3): 132-7. doi:10.1191/0961203306lu2283rr. PMID 16634365. S2CID 25736411.. *^ Jimenez, SA; Derk, CT (Jan 6, 2004). " ... 978-3-11-022864-9. .. *^ Worman, HJ; Courvalin, JC (June 2003). "Antinuclear antibodies specific for primary biliary cirrhosis ...
2009). "Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip". Am. J. Hum. ... The 3' UTR of Sec-containing genes have a common stem-loop structure, the sec insertion sequence (SECIS), which is necessary ... GPx-3 belongs to the glutathione peroxidase family, which functions in the detoxification of hydrogen peroxide. It contains a ... 48 (3-4): 129-30. PMID 11934214. Fullerton JM, Tiwari Y, Agahi G, et al. (2010). "Assessing oxidative pathway genes as risk ...
As in DNA, mRNA genetic information is in the sequence of nucleotides, which are arranged into codons consisting of three base ... An example in humans is the apolipoprotein B mRNA, which is edited in some tissues, but not others. The editing creates an ... and three prime untranslated region (3' UTR), respectively. These regions are transcribed with the coding region and thus are ... when Moderna Therapeutics was founded and managed to raise almost a billion dollars in venture funding in its first three years ...
Strukturno, gp130 se sastoji od pet fibronektin tip-III domena i jednog imunoglobulinu-sličnog C2-tipa domena na njegovom ... Aktivin i inhibin • ADAM • Alfa 1-antihimotripsin • Apolipoprotein H • CD70 • Asijaloglikoprotein • Avidin • B-ćelijski ... Barton VA, Hudson KR, Heath JK (1999). „Identification of three distinct receptor binding sites of murine interleukin-11.". J. ... Taj kompleks od 3 proteina se homodimerizuje da formira heksamerni kompleks koji može da proizvede nizvodne signale.[3] Postoje ...
structures of apolipoprotein a-ii and a lipid surrogate complex provide insights into apolipoprotein-lipid interactions ... "Entrez Gene: APOA2 apolipoprotein A-II".. *^ Pussinen PJ, Jauhiainen M, Metso J, Pyle LE, Marcel YL, Fidge NH, Ehnholm C (Jan ... Apolipoprotein A-II is a protein that in humans is encoded by the APOA2 gene.[5] ... apolipoprotein receptor binding. • high-density lipoprotein particle receptor binding. • cholesterol binding. • protein binding ...
... of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins ... ISBN 978-3-540-22569-0. *↑ Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and ... 1.007 g/cm3 (24 °C) [3] 0.8744 g/cm3 (41.5 °C)[1]. 0.8679 g/cm3 (50 °C) ... on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials ...
APOE: Apolipoprotein E, gene associated with Alzheimer's disease. *BCKDHA: Branched chain keto acid dehydrogenase E1, alpha ...
... research has been put on concerning apolipoprotein E genotypes; this polymorphism has three alleles (*e2, *e3, and *e4)and was ... Specifically too, the apolipoprotein *e4 allele is linked to Alzheimer's disease as well. Also, there is increased coronary ... Poet laureate of San Francisco Janice Mirikitani has published three volumes of poems. Lawson Fusao Inada was named poet ... Japanese Americans were among the three largest Asian American ethnic communities during the 20th century; but, according to ...
Antithrombin-III. *Lipoprotein lipase. *Apolipoproteins. *Growth factors. *Chemokines. The enzymes and proteins listed above ... 3. p. 345-359 *^ Ebong, Eno; Macaluso FP; Spray DC; Tarbell JM (August 2011). "Imaging the Endothelial Glycocalyx In Vitro By ...
In step three of the synthesis process, the N-acetyl-glucosamine-6-phosphate is isomerized, which will change N-acetyl- ... Attached to the N-acetylmuramic acid is a peptide chain of three to five amino acids. The peptide chain can be cross-linked to ... 178 (3): 768-73. PMC 177723. PMID 8550511.. *^ Ryan KJ, Ray CG, eds. (2004). Sherris Medical Microbiology (4th ed.). McGraw ... Some archaea have a similar layer of pseudopeptidoglycan (also known as pseudomurein), in which the sugar residues are β-(1,3) ...
... s comprise the main components of three commercially important waxes: carnauba wax, candelilla wax, and beeswax.[1] ... and astaxanthin-rich extract from the marine copepod Calanus finmarchicus attenuates atherogenesis in female apolipoprotein E- ... 5n-3, 22:5n-3 and 22:6n-3. The fatty acids of wax esters of certain zooplankton largely reflects the fatty acids of ... finmarchicus could serve as a relevant source of the healthy omega-3 fatty acids EPA, DHA and SDA. 86% of the oil from C. ...
Heavy chains γ, α and δ have a constant region composed of three tandem (in a line) Ig domains, and a hinge region for added ... Basically, the antibody paratope is polygenic, made up of three genes, V, D, and J. Each paratope locus is also polymorphic, ... Differences, between the variable domains, are located on three loops known as hypervariable regions (HV-1, HV-2 and HV-3) or ... 31 (3-4): 263-278. doi:10.1081/IMM-120016245. PMID 12472184.. *^ a b Brehm-Stecher B, Johnson E (2004). "Single-cell ...
a b c Incidence and subtypes of dementia in three elderly populations of central Spain. Journal of the Neurological Sciences. ... Apolipoprotein E, Dementia, and Cortical Deposition of Beta-amyloid Protein. The New England Journal of Medicine. 1995;333(19): ... a b Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proceedings ... Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial ...
In the three adults who are reported to have succumbed, the doses were 20-30 g.[46][51][52] However, two adult survivors ... and apolipoproteins A and B.[24] ... 3-4. Retrieved 2007-10-12.. [dead link] *^ a b c Mattson RH, ... 30 (3): 255-8. doi:10.1001/archneur.1974.00490330063011. PMID 4812959.. *^ a b c d e van Heijst, A. N.; W. de Jong; R. ... 3: 23-8. PMID 13902356.. *^ a b Zesiewicz TA, Elble R, Louis ED, Hauser RA, Sullivan KL, Dewey RB, Ondo WG, Gronseth GS, Weiner ...
"Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis". Nature ... 3: 1349. doi:10.1038/srep01349. PMC 3583002. PMID 23443229.. *^ Henricks, P. A; Engels, F; Van Der Vliet, H; Nijkamp, F. P ( ... 3: 1349. doi:10.1038/srep01349. PMC 3583002. PMID 23443229.. *^ Thomas, Biju; Rutman, Andrew; Hirst, Robert A; Haldar, Pranab; ... doi:10.1016/S0092-8674(00)81574-3. PMID 9568715.. *^ Itoh, T; Fairall, L; Amin, K; Inaba, Y; Szanto, A; Balint, B. L; Nagy, L; ...
"Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression". Gastroenterology. 125 (2): 544-55. doi:10.1016/ ... 18 (3): 289-97. doi:10.1097/MOL.0b013e3281338d08. PMID 17495603.. *. Seol W, Choi HS, Moore DD (Jan 1995). "Isolation of ... doi:10.1016/S0016-5085(03)00388-3. PMID 12806625.. *. Holt JA, Luo G, Billin AN, Bisi J, McNeill YY, Kozarsky KF, Donahee M, ... Polycyclic aromatic hydrocarbons (e.g., 3-methylcholanthrene, benzo[a]pyrene, benzanthracenes, benzoflavones (e.g., beta- ...
"Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip". American Journal of ... 283 (3): 1679-91. doi:10.1074/jbc.M705457200. PMID 17974561.. *. Johne C, Matenia D, Li XY, Timm T, Balusamy K, Mandelkow EM ( ... An exon 3 c.46C,T mutation leading to p.Arg16Stop.[8] This mutation may result in a truncated nonfunctional protein. Blast ... "Spred-1 negatively regulates interleukin-3-mediated ERK/mitogen-activated protein (MAP) kinase activation in hematopoietic ...
Zhang, Jianying; Herscovitz Haya (February 2003). "Nascent lipidated apolipoprotein B is transported to the Golgi as an ... Linnik, K M; Herscovitz H (August 1998). "Multiple molecular chaperones interact with apolipoprotein B during its maturation. ... The network of endoplasmic reticulum-resident chaperones (ERp72, GRP94, calreticulin, and BiP) interacts with apolipoprotein b ... CysLT (1, 2) • LTB4 (1, 2) • FPRL1 • OXE • Prostaglandin (DP (1, 2), EP (1, 2, 3, 4), FP) • Prostaciklin • Tromboksan ...
APOA4: Apolipoprotein A-IV. *Ataksijska telangiektazija,mutirana ATM (uključujući kkomplementacijske grupe A, C i D) ...
"Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis". Nat. ... 95 (3): 1281-7. doi:10.1172/JCI117778. PMC 441467. PMID 7883976.. الوسيط ,CitationClass=. تم تجاهله (مساعدة). ... 57 (1): 3-9. doi:10.1016/S0952-3278(97)90485-3. PMID 9250601.. الوسيط ,CitationClass=. تم تجاهله (مساعدة). ... 9 (3): 213-28. doi:10.1023/A:1018666522787. PMID 9204553.. الوسيط ,CitationClass=. تم تجاهله (مساعدة). ...
"Apolipoprotein C-III(Lys58----Glu). Identification of an apolipoprotein C-III variant in a family with ... Apolipoprotein C-III also known as apo-CIII, and apolipoprotein C3, is a protein that in humans is encoded by the APOC3 gene. ... Apolipoprotein+C-III at the US National Library of Medicine Medical Subject Headings (MeSH) Human APOC3 genome location and ... Zannis VI, Cole FS, Jackson CL, Kurnit DM, Karathanasis SK (Jul 1985). "Distribution of apolipoprotein A-I, C-II, C-III, and E ...
Biophysical analysis of apolipoprotein E3 variants linked with development of type III hyperlipoproteinemia.. Georgiadou D1, ... Biophysical Analysis of Apolipoprotein E3 Variants Linked with Development of Type III Hyperlipoproteinemia ... Biophysical Analysis of Apolipoprotein E3 Variants Linked with Development of Type III Hyperlipoproteinemia ... Biophysical Analysis of Apolipoprotein E3 Variants Linked with Development of Type III Hyperlipoproteinemia ...
Clinical mass spectrometry test for apolipoprotein C-III proteoforms. Printer-friendly version ... The new apolipoprotein C III MS test will transform clinical research by enabling fast and cost effective screening of apoC III ... translationOur recent studies have revealed strong associations between relative abundance of a specific apolipoprotein C III ... lipid metabolism and cardiometabolic riskWe propose to develop and demonstrate a low costhigh throughput MALDI TOF MS apoC III ...
Production of Apolipoprotein C-III Knockout Rabbits using Zinc Finger Nucleases. Dongshan Yang1, Jifeng Zhang1, Jie Xu1, ... Apolipoprotein (Apo) C-III (ApoCIII) is a small O-glycosylated secretory protein that is synthesized mainly in the liver and ... Apolipoprotein (Apo) C-III (ApoCIII) resides on the surface of plasma chylomicron (CM), very low density lipoprotein (VLDL) and ... Yang, D., Zhang, J., Xu, J., Zhu, T., Fan, Y., Fan, J., Chen, Y. E. Production of Apolipoprotein C-III Knockout Rabbits using ...
Isoelectric focusing resolves apoC-III into three isoforms: apoC-III0, apoC-III1, and apoC-III2. ApoC-III1 was investigated in ... Apolipoprotein (apo)-C-III is an 8.8-kDa glycoprotein synthesized by the liver and intestines. ApoC-III is highly associated ... Both VLDL apoC-III FCR and PR were independent determinants of VLDL apoC-III concentration. The increase in VLDL apoC-III FCR ... Plasma apolipoprotein C-III transport in central obese men: associations with very-low density lipoprotein apolipoprotein B and ...
2015 May-Jun;9(3):360-7. doi: 10.1016/j.jacl.2014.12.001. Epub 2014 Dec 11. Randomized Controlled Trial; Research Support, N.I. ... apoB and apoC-III were significantly decreased by the high dose relative to placebo and low dose (P , .01), as was very low- ... The high- and low-dose effects differed significantly for heparin-precipitated apoC-III, LpB, LpA-I, and apoB/apoA-I ratio (P ... The effects of 3.4 g/d EPA + DHA on apoB and apoC-III may reduce atherosclerotic plaque progression in individuals with ...
Apolipoprotein D is a protein that in humans is encoded by the APOD gene. Apolipoprotein D (Apo-D) is a component of high ... Apolipoprotein D, 978-613-3-98067-9, Please note that the content of this book primarily consists of articles available from ... density lipoprotein that has no marked similarity to other apolipoprotein sequences. ... Apolipoprotein D is a protein that in humans is encoded by the APOD gene. Apolipoprotein D (Apo-D) is a component of high ...
Title Apolipoprotein C-III, an important player in lipoprotein metabolism. Author(s) Gotto, A.M. ; Jackson, A.S. ; Catapano, A. ...
Yu Du, Li Wang, Shuyi Si, Yuan Yang, Bin Hong, A novel compound 4010B-30 upregulates apolipoprotein A-I gene expression through ... To identify the mechanisms by which cocoa induces HDL levels and since apolipoprotein AI (ApoAI) is the major protein in HDLs, ... and NFY-mediated transcription of apolipoprotein AI in human cells. Authors. *. Carlota Oleaga,. *Department of Biochemistry ... 3. Torsten Bohn, Gordon J. McDougall, Amparo Alegría, Marie Alminger, Eva Arrigoni, Anna-Marja Aura, Catarina Brito, Antonio ...
Do Apolipoprotein E Polymorphisms Influence Risk of Cognitive Decline by Modulating Omega-3 Fatty Acid Metabolism?. The safety ... Do Apolipoprotein E Polymorphisms Influence Risk of Cognitive Decline by Modulating Omega-3 Fatty Acid Metabolism?. ... ii) 13C-DHA metabolism changes while on a dietary supplement of EPA+DHA; iii) Better cognitive performance occurs while on EPA+ ... the epsilon 4 allele of apolipoprotein E (ApoE4) is associated with twice the prevalence of late-onset Alzheimers disease (AD ...
Chemicals/CAS: apolipoprotein E3 (Leidein); Apolipoprotein E3; Apolipoproteins E; Bile Acids and Salts; cafestol, 469-83-0; ... Biology · Animals · Apolipoprotein E3 · Apolipoproteins E · Bile Acids and Salts · Cholesterol · Diet · Diterpenes · Feces · ... Cafestol increases serum cholesterol levels in apolipoprotein E*3- leiden transgenic mice by suppression of bile acid synthesis ... In apoE*3-Leiden mice, serum cholesterol was statistically significantly increased by 33% on the low- and by 61% on the high- ...
We have discovered that natural variant versions of Apolipoprotein L1 (APOL1) that protect humans against infection by the ... This project intends to characterize the function of a family of proteins termed Apolipoproteins L, or in short ""APOLs"". A ... "We have discovered that natural variant versions of Apolipoprotein L1 (APOL1) that protect humans against infection by the ... Role of Apolipoproteins L in immunity and disease). Reporting period: 2018-09-01 to 2020-02-29 ...
Low-density lipoprotein (LDL) that contains apolipoprotein (apo) C-III makes up only 10% to 20% of plasma LDL but has a ... "Low-Density Lipoproteins Containing Apolipoprotein C-III and the Risk of Coronary Heart Disease." Circulation 124 (19) (October ... Low-Density Lipoproteins Containing Apolipoprotein C-III and the Risk of Coronary Heart Disease. ... the relative risks for the top versus bottom quintile of LDL with apoC-III were greater than those for LDL without apoC-III. ...
To assess the consequences of epilepsy and APOE genotype on neurons, we counted neurons in cortical layers III to VI of three ... Three images per slide (40X magnification) were captured at identical exposure settings, using a Nikon Eclipse E600 microscope ... Liu L, Aboud O, Jones RA, Mrak RE, Griffin ST, Barger SW: Apolipoprotein E expression is elevated by interleukin 1 and other ... Marz W, Scharnagl H, Kirca M, Bohl J, Gross W, Ohm TG: Apolipoprotein E polymorphism is associated with both senile plaque load ...
Background: Apolipoprotein C-III (apoC-III) inhibits lipoprotein lipase activity and hepatic uptake of triglyceride-rich ... Abstract 19030: Apolipoprotein C-III is Significantly Reduced by Prescription Omega-3 Free Fatty Acids (Epanova) in Patients ... Abstract 19030: Apolipoprotein C-III is Significantly Reduced by Prescription Omega-3 Free Fatty Acids (Epanova) in Patients ... Abstract 19030: Apolipoprotein C-III is Significantly Reduced by Prescription Omega-3 Free Fatty Acids (Epanova) in Patients ...
... Meyers, Nathan L. ... ApoC-III elevates TG in part by inhibiting LPL. ApoC-III likely inhibits LPL by competing for lipid binding. To probe this, we ... ApoC-III adsorption increased surface pressure by upward of 18 mN/m at phospholipid/TG/water interfaces. ApoC-III was retained ... Increased apoC-III expression in the hypertriglyceridemic state allows apoC-III to accumulate on lipoproteins and inhibit LPL ...
Scavenger receptor function of mouse Fcγ receptor III contributes to progression of atherosclerosis in apolipoprotein E ... In this report, we show that apolipoprotein E (apoE)-CD16 double knockout (DKO; apoE-CD16 DKO) mice have reduced ...
Apolipoprotein C-Iii Composition of Triglyceride-Rich Lipoproteins and Their Substrate Efficiency with Lipoprotein Lipase FM ... FM Dodson, J Stocks, G Holdsworth, DJ Galton; Apolipoprotein C-Iii Composition of Triglyceride-Rich Lipoproteins and Their ...
ApoC-III1 and apoC-III2 are the most abundant C-III apolipoproteins in human plasma compared with apoC-III0. Given that apoC- ... Apolipoproteins C-III and A-V as Predictors of Very-Low-Density Lipoprotein Triglyceride and Apolipoprotein B-100 Kinetics. ... Apolipoproteins C-III and A-V as Predictors of Very-Low-Density Lipoprotein Triglyceride and Apolipoprotein B-100 Kinetics ... Apolipoproteins C-III and A-V as Predictors of Very-Low-Density Lipoprotein Triglyceride and Apolipoprotein B-100 Kinetics ...
The American Heart Association is a qualified 501(c)(3) tax-exempt organization.. *Red Dress™ DHHS, Go Red™ AHA; National Wear ... Endogenously Decreasing Tissue n-6/n-3 Fatty Acid Ratio Reduces Atherosclerotic Lesions in Apolipoprotein E-Deficient Mice by ... Endogenously Decreasing Tissue n-6/n-3 Fatty Acid Ratio Reduces Atherosclerotic Lesions in Apolipoprotein E-Deficient Mice by ... Endogenously Decreasing Tissue n-6/n-3 Fatty Acid Ratio Reduces Atherosclerotic Lesions in Apolipoprotein E-Deficient Mice by ...
Nox2 modification of LDL is essential for optimal apolipoprotein B-mediated control of agr type III Staphylococcus aureus ... We determined whether two host defense factors that inhibit AIP1-induced agrI signaling, Nox2 and apolipoprotein B (apoB), also ...
We studied the independent and combined effects of fish oils and atorvastatin on the metabolism of HDL apolipoprotein A-I (apo ... Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and ...
Serum amyloid A, apolipoprotein C (apoC-III) and apolipoprotein A-II (apoA-II) were selected to confirm the proteomics results ... Lv, P., Zhao, M., Liu, Y., Jin, H., Cui, W., Fan, C., Teng, Y., Zheng, L., Huang, Y.Apolipoprotein C-III in the high-density ... Lv, P., Zhao, M., Liu, Y., Jin, H., Cui, W., Fan, C., Teng, Y., Zheng, L., Huang, Y.Apolipoprotein C-III in the high-density ... Apolipoprotein C-III in the high-density lipoprotein proteome of cerebral lacunar infarction patients impairs its anti- ...
Knockdown of hMDM apoE inhibited basal cholesterol efflux by 20% without altering apolipoprotein-AI mediated cholesterol efflux ... Apolipoprotein-E (apoE) expression may be associated with apoptosis resistance. Since macrophages constitutively synthesize ... In these experiments, staurosporine-induced caspase-3 activation was increased by 49% in apoE null compared to wild type mBMDM ... In conclusion, apoE expression modulates capase-3 activity, but this has no significant impact on sensitivity to apoptosis and ...
Apolipoprotein C-III (apoC-III) is a key regulator of lipoprotein metabolism. We investigated whether subspecies of HDL defined ... High-Density Lipoprotein Subspecies Defined by Presence of Apolipoprotein C-III and Incident Coronary Heart Disease in Four ... ApoC-III was found on 6% to 8% of apoA-I. The 2 HDL subspecies showed opposing associations, with risk of CHD in each of the ... Our findings from 4 prospective studies support the hypothesis that apoC-III may mark a subfraction of HDL that is associated ...
Type III hyperlipoproteinemia (HLP) is a genetic disorder of lipid metabolism in humans in which the primary molecular defect ... is a mutation(s) in apolipoprotein (apo) E that causes defective... ... The Apolipoprotein E Cys-142 Mutant: Role in Dominant Inheritance of Type III Hyperlipoproteinemia and Expression in Transgenic ... In: Sirtori C.R., Franceschini G., Brewer B.H. (eds) Human Apolipoprotein Mutants III. NATO ASI Series (Series H: Cell Biology ...
Modulation of hepatic apolipoprotein B, 3-hydroxy-3-methylglutaryl-CoA reductase and low-density lipoprotein receptor mRNA and ... Modulation of hepatic apolipoprotein B, 3-hydroxy-3-methylglutaryl-CoA reductase and low-density lipoprotein receptor mRNA and ... Modulation of hepatic apolipoprotein B, 3-hydroxy-3-methylglutaryl-CoA reductase and low-density lipoprotein receptor mRNA and ... Modulation of hepatic apolipoprotein B, 3-hydroxy-3-methylglutaryl-CoA reductase and low-density lipoprotein receptor mRNA and ...
Overproduction of intestinal lipoprotein containing apolipoprotein B-48 in: impact of dietaryn-3 fatty acidsPsammomys obesus: ... fish oil feeding resulted in diminished triglyceride-rich lipoprotein assembly and apolipoprotein (apo) B-48 biogenesis, ... Our data highlight the beneficial impact of n-3 fatty acids on adverse effects of the metabolic syndrome and emphasise their ... We therefore tested the hypothesis that n-3 fatty acids improve the various events governing intra-enterocyte lipid transport ...
Very Low-Density Lipoprotein Native Apolipoprotein C-III from human plasma found in VLDL and chylomicrons. Involved in ... Apolipoprotein C-III, Human Plasma, Very Low-Density Lipoprotein. 178461 Sigma-AldrichApolipoprotein C-III, Human Plasma, Very ... Apo C-III. Description. Native apolipoprotein C-III from human plasma. Present in normal plasma at 80-150 µg/ml. Major protein ... Native apolipoprotein C-III from human plasma. Major protein of VLDL and chylomicrons. Involved in the uptake of triglycerides ...
... multiphoton microscopy for three-dimensional imaging of lymphocyte recruitment into apolipoprotein-E-deficient mouse carotid ... multiphoton microscopy for three-dimensional imaging of lymphocyte recruitment into apolipoprotein-E-deficient mouse carotid ... Two recent elegant studies have shown that in apolipoprotein-E- deficient mice, the lamina adventitia is a major site of ...
  • Apolipoprotein (Apo) C-III (ApoCIII) resides on the surface of plasma chylomicron (CM), very low density lipoprotein (VLDL) and high density lipoproteins (HDL). (jove.com)
  • Apolipoprotein (apo) distribution and lipoprotein (Lp)-associated markers of inflammation, such as lipoprotein-associated phospholipase A2 (Lp-PLA2), influence the atherogenicity of circulating lipids and lipoproteins. (nih.gov)
  • Apolipoprotein C-III (apoC-III) inhibits lipoprotein lipase activity and hepatic uptake of triglyceride-rich lipoproteins. (ahajournals.org)
  • jlr) We propose that aromatic residues in the C-terminal half of apoC-III mediate binding to TG-rich lipoproteins. (diva-portal.org)
  • Increased apoC-III expression in the hypertriglyceridemic state allows apoC-III to accumulate on lipoproteins and inhibit LPL by preventing binding and/or access to sub-strate. (diva-portal.org)
  • Apolipoprotein (apo)C-III, a glycoprotein synthesized by the liver and intestine, plays a central role in regulating the metabolism of triglyceride-rich lipoproteins (TRLs) including VLDL and their remnants in plasma. (ahajournals.org)
  • Effects of conjugated equine estrogen with and without three different progestogens on lipoproteins, high-density lipoprotein subfractions, and apolipoprotein A-I. (semanticscholar.org)
  • Plasma apolipoprotein (Apo) C-III is a major component of TG-rich lipoproteins (chylomicrons and very low density lipoprotein) and a minor component of high density lipoprotein. (biomedcentral.com)
  • Therapy based on apolipoprotein A-I (apoA-I), the major protein component of high-density lipoproteins, results in AVS regression in experimental models. (springer.com)
  • OBJECTIVE To describe and compare the associations of serum lipoproteins and apolipoproteins with diabetic retinopathy. (diabetesjournals.org)
  • Does Incorporation of EPA and DHA in Lipoproteins Differ According to Apolipoprotein E Genotype? (clinicaltrials.gov)
  • This period was chosen because the 3 class of lipoproteins (VLDL, LDL and HDL) have different concentrations in TG, phospholipids and cholesteryl esters and to fully investigate lipoprotein fatty acid changes, one month of supplementation is needed to change EPA and DHA in all lipid classes. (clinicaltrials.gov)
  • Objective: Prescription omega-3 acid ethyl esters (P-OM3) and extended release niacin (ERN) both have beneficial effects on plasma lipids and lipoproteins. (elsevier.com)
  • Apolipoproteins provide structural integrity to lipoproteins and shield the water-repellent (hydrophobic) lipids at their center. (labtestsonline.org)
  • Proinflammatory response by the interaction between ENO1 and apolipoprotein B (apoB) was tested in vitro and in vivo using peripheral blood mononuclear cells and a K/BxN serum transfer arthritis model and low-density lipoproteins receptor (LDLR) knockout mice. (bmj.com)
  • Cinnamon extract inhibits the postprandial overproduction of apolipoprotein B48-containing lipoproteins in fructose-fed animals. (greenmedinfo.com)
  • Apolipoprotein E (ApoE), a constituent of the lipoproteins, may be relevant in herpes simplex virus type 1 (HSV-1) infection of the central nervous system (CNS), since HSV-1 binds to human serum ApoE lipoproteins. (asm.org)
  • Apolipoprotein E (ApoE) is a constituent of very-low-density lipoprotein synthesized by the liver ( 29 ) and of members of a subclass of high-density lipoproteins involved in cholesterol transport among cells ( 18 ). (asm.org)
  • Apolipoprotein E (apoE) is a major protein of the lipoprotein transport system that plays important roles in lipid homeostasis and protection from atherosclerosis. (nih.gov)
  • Mutations in the 136-150 region of the N-terminal domain of apoE, reduce its low density lipoprotein (LDL) receptor binding capacity and have been linked with lipoprotein disorders, such as type III hyperlipoproteinemia (HLP) in humans. (nih.gov)
  • IMPLICATIONS: This project will help explain the apparent link that is newly emerging between ApoE polymorphisms, altered omega-3 fatty acid metabolism and risk of cognitive decline, and should help in the development of nutraceutical-based clinical trials using fish oil for the elderly. (clinicaltrials.gov)
  • ApoE*3-Leiden, heterozygous low density lipoprotein-receptor (LDLR+/-) knockout, or wild-type (WT) C57BL/6 mice were fed a high- (0.05% wt/wt) or a low- (0.01% wt/wt) cafestol diet or a placebo diet for 8 weeks. (tudelft.nl)
  • In apoE*3-Leiden mice, serum cholesterol was statistically significantly increased by 33% on the low- and by 61% on the high-cafestol diet. (tudelft.nl)
  • To investigate the mechanism of this effect, apoE*3-Leiden mice were fed a high-cafestol or a placebo diet for 3 weeks. (tudelft.nl)
  • In conclusion, cafestol increases serum cholesterol levels in apoE*3-Leiden mice by suppression of the major regulatory enzymes in the bile acid synthesis pathways, leading to decreased LDLR mRNA levels and increased secretion of hepatic cholesterol esters. (tudelft.nl)
  • With an eye toward defining ways in which APOE ε3 alleles may foster neuronal well-being in epilepsy and/or APOE ε4 alleles exacerbate neuronal decline, neuronal and glial characteristics were studied in temporal lobectomy specimens from epilepsy patients of either APOE ε4,4 or APOE ε3,3 genotype. (springer.com)
  • APOE ε3,3 age 17). (springer.com)
  • Our findings of neuronal and glial events, which correlate with lesser neuronal DNA damage and larger, more robust neurons in epilepsy patients of APOE ε3,3 genotype compared to APOE ε4,4 genotype carriers, are consistent with the idea that the APOE ε 3,3 genotype better protects neurons subjected to the hyperexcitability of epilepsy and thus confers less risk of AD (Alzheimer's disease). (springer.com)
  • Type III hyperlipoproteinemia (HLP) is a genetic disorder of lipid metabolism in humans in which the primary molecular defect is a mutation(s) in apolipoprotein (apo) E that causes defective interaction of apoE with lipoprotein receptors and an accumulation of cholesterol-rich β-VLDL in the blood (Mahley and Rall, 1989). (springer.com)
  • Most often, type III HLP is associated with homozygosity for an apoE mutant that has cysteine instead of arginine at residue 158, i.e ., with recessive inheritance. (springer.com)
  • Many rare mutants of apoE have now been described (Fig. 1), some of which are also associated with type III HLP. (springer.com)
  • In most of these rare instances, type III HLP is transmitted in a dominant fashion, i.e ., heterozygosity for the apoE mutant is sufficient for expression of the disorder. (springer.com)
  • One of these rare apoE variants (cysteine instead of arginine at residue 142) has been found in a single family in which seven members spanning four generations are heterozygous for this apoE variant and all seven have type III HLP (Havel et al . (springer.com)
  • 1989). Because of the unusual nature of the disorder in this family, we undertook investigations of the properties of the apoE Cys-142 mutant to determine its role in the expression of type III HLP. (springer.com)
  • The 4 allele of the apolipoprotein E gene (ApoE) is a genetic risk factor for late-onset AD. (eurekaselect.com)
  • The action of n-3 PUFA on the aging brain might therefore differ according to ApoE polymorphism. (eurekaselect.com)
  • Apolipoprotein E, type epsilon 4 allele (ApoE epsilon 4), is associated with late-onset sporadic Alzheimer's disease (AD) in French patients. (unboundmedicine.com)
  • Here, we identify a role for apolipoprotein E (ApoE) in age-associated impairment of bone fracture healing and osteoblast differentiation, and we investigate the mechanism by which ApoE alters these processes. (jci.org)
  • Apolipoprotein E (APOE4) is the most important known genetic risk for AD and is prevalent in 20-25% of Canadians, but at present, knowing an individual's ApoE genotype does not help the diagnosis, treatment or prevention of AD. (clinicaltrials.gov)
  • An association between apolipoprotein E ( apoE ) gene polymorphism and temperament has been found in the Young Finns cohort. (scirp.org)
  • S. J. Tsai, Y. W. Yu and C. J. Hong, "Personality Traits in Young Female Apolipoprotein E (apoE) Epsilon4 and Non-Epsilon4 Carriers," American Journal of Medical Genetics. (scirp.org)
  • Two distal downstream enhancers controlling astrocyte expression of the human apolipoprotein E (apoE) gene in the brain were identified by analysis of transgenic mice generated with various constructs of the apoE/C-I/C-IV/C-II gene cluster. (jneurosci.org)
  • Apolipoprotein E (apoE) is a protein ( M r = 35,000) that functions in the CNS. (jneurosci.org)
  • To test this hypothesis, we investigated the effect of repeated systemic inoculations with Porphyromonas gingivalis ( Pg ), a putative periodontal pathogen, on the progression of atherosclerosis in heterozygous apolipoprotein E-deficient (ApoE +/− ) mice. (ahajournals.org)
  • To address this question, in this study, we examine for the first time the renoprotective actions of alagebrium in diabetic RAGE apolipoprotein E ( apoE ) double-knockout (KO) mice, with a particular emphasis on glomerular fibrosis and inflammation, comparing its effects with those of the ACE inhibitor, quinapril. (diabetesjournals.org)
  • Male ApoE −/− mice (3 months old) were purchased from the Animal Resources Centre, Perth, Australia. (frontiersin.org)
  • LDL-C (-27%), lathosterol (-40%), apoB (- 22%), apoC-III (-37%), and apoE (-24%) and modestly decreased the levels of HDL-C (-12%) and apoA-I (-11%) (percent relative to the average pretreatment and posttreatment baseline values) but did not affect the levels of TG, VLDL-C, the lathosterol/TC ratio, or LCAT activity. (tudelft.nl)
  • LDL-C, apoB, apoC-III, and apoE to simvastatin in the FHC swines is similar to that observed in humans, although the drug is less potent and efficacious in swine, while the results are different from those in humans with regard to the remaining parameters. (tudelft.nl)
  • probably the gene for apolipoprotein E (APOE), as our recent data suggest, and upon which we comment below. (bmj.com)
  • 3 In this issue, the article by Aucan et al offers support for involvement of APOE in the development of severe malaria: people carrying an APOE-ε3/ε4 genotype may be more likely than those with the other main genotypes to suffer extremely severe malaria (cerebral malaria and severe anaemia). (bmj.com)
  • 4, 5 We tentatively suggested 5 an explanation based on the usage by each of these viruses, 7, 10 and by the malaria protozoon, 3 of the same cell entry mediators as those of apoE. (bmj.com)
  • The fourth and perhaps the most important recently discovered gene linked to AAlzheimers disease is the Apolipoprotein E (ApoE) gene on chromosome 19, which has been associated with many lateonset familial cases of Alzheimers disease as well as sporadic cases in the over-60 age group. (slideshare.net)
  • In humans, there are three alleles of the apoE gene (designated ε2, ε3, and ε4), encoding the respective isoforms of the protein (E2, E3, and E4) ( 19 ). (asm.org)
  • ApoE may play an important modulatory function in the central nervous system (CNS), because while in the peripheral nervous system several other apolipoproteins are involved in lipid transport, in the CNS there is less redundancy of such molecules ( 19 , 26 ). (asm.org)
  • First, it has been reported that sufferers from cold sores are more likely to carry the apoE ε4 allele than controls ( 3 ). (asm.org)
  • Apolipoprotein E ( APOE ) polymorphisms are unequivocally associated with risk for Alzheimer's disease (AD). (bmj.com)
  • MMSE scores at wave 3 and the difference in MMSE between baseline and at the third assessment wave were not different across APOE genotypes. (bmj.com)
  • Alzheimer's disease risk is unequivocally associated with polymorphisms in the apolipoprotein E ( APOE ) gene (chromosome 19q13.2). (bmj.com)
  • Two polymorphisms in the coding region of APOE result in three major isoforms of the protein, apoE2, apoE3 (the most common isoform), and apoE4. (bmj.com)
  • abstract = "The nicotine-derived nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone (NNK) is one of the most potent lung carcinogens in rodents. (elsevier.com)
  • Apolipoprotein C-III also known as apo-CIII, and apolipoprotein C3, is a protein that in humans is encoded by the APOC3 gene. (wikipedia.org)
  • Apolipoprotein D is a protein that in humans is encoded by the APOD gene. (morebooks.de)
  • Tripalmitin also increased hepatic expression of the apolipoprotein B gene, implying an increased production of LDL via very-low-density lipoprotein (VLDL) and decreased removal of LDL in animals fed this fat. (biochemj.org)
  • The mechanisms underlying this gene-by-diet interaction on AD risk may involve impaired fatty acids and cholesterol transport, altered metabolism of n-3 PUFA, glucose or ketones, or modification of other risk factors of AD in 4 carriers. (eurekaselect.com)
  • The effects of polymorphisms in the lipoprotein lipase (LPL) gene (HindIII and S447X) and in the apolipoprotein (apo) AI-CIII gene cluster (G75A and C1100T) on levels of fasting plasma triglycerides, apoCIII, high density lipoprotein cholesterol (HDL-C), and apoAI were examined in 315 healthy men and women from Iceland. (unboundmedicine.com)
  • Both apolipoprotein (Apo) C-III gene polymorphism and alcohol consumption have been associated with increased serum triglyceride (TG) levels, but their interactions on serum TG levels are not well known. (biomedcentral.com)
  • Apolipoprotein C-II or apolipoprotein C2 is a protein that in humans is encoded by the APOC2 gene. (wikipedia.org)
  • 1986). "The structure of the human apolipoprotein C-II gene. (wikipedia.org)
  • Page NM, Butlin DJ, Lomthaisong K and Lowry PJ: The human apolipoprotein L gene cluster: Identification, classification, and sites of distribution. (spandidos-publications.com)
  • Monajemi H, Fontijn RD, Pannekoek H and Horrevoets AJ: The apolipoprotein L gene cluster has emerged recently in evolution and is expressed in human vascular tissue. (spandidos-publications.com)
  • The aim of this study was to compare patients with coronary artery disease (CAD) to healthy objects, in order to explore a possible association between CAD and the variants in the gene encoding cholesterol ester transfer protein (CETP), apolipoprotein E (Apo E) and lipoprotein lipase (LPL). (wiley.com)
  • Unexpectedly, truncated apolipoprotein L-I devoid of the serum resistance gene interacting domain, which was previously shown to kill human infective trypanosomes, was not trypanolytic in transgenic mice despite being coexpressed with human apolipoprotein A-I and Hpr and incorporated into HDLs. (rupress.org)
  • The apolipoprotein E gene ε4 all. (bio-medicine.org)
  • The apolipoprotein E gene ε4 allele is considered a negative fact. (bio-medicine.org)
  • The apolipoprotein E gene ε4 allele is considered a negative factor for neural regeneration in late-onset Alzheimer's disease cases. (bio-medicine.org)
  • A research team from Department of Neurology, Peking University Shenzhen Hospital in China pointed out a non-invasive and fast method to genotype large samples to help to elucidate the role of apolipoprotein E gene ε4 allele in neural regeneration in the cases with late-onset Alzheimer's disease. (bio-medicine.org)
  • Hepatic cell-specific expression of the human apolipoprotein B (apoB) gene is controlled by at least four cis-acting elements located between positions -128 and +122 [Chuang, S. S., and Das, H. K. (1996) Biochem. (unthsc.edu)
  • A negative cis-acting element (+20 to +40) is located in the first nontranslated exon of the human apoB gene, and apoB regulatory factor-3 (BRF-3) interacts with this. (unthsc.edu)
  • Fingerprint Dive into the research topics of 'Purified apolipoprotein B gene regulatory factor-3 is DNA topoisomerase I'. Together they form a unique fingerprint. (unthsc.edu)
  • Purified apolipoprotein B gene regulatory factor-3 is DNA topoisomerase I . European Journal of Biochemistry , 263 (3), 773-781. (unthsc.edu)
  • No associations were found for four HL gene polymorphisms and two LPL gene polymorphisms and type III HLP. (tudelft.nl)
  • Apolipoprotein E genotype and the association between C-reactive protein and postoperative delirium: Importance of gene-protein interactions. (harvard.edu)
  • There are two forms, apolipoprotein B-100 and apolipoprotein B-48, both derived from a single gene. (harvard.edu)
  • The gene occurs in three different forms: apoE2, apoE3, and apoE4. (slideshare.net)
  • The effects of 3.4 g/d EPA + DHA on apoB and apoC-III may reduce atherosclerotic plaque progression in individuals with elevated triglycerides. (nih.gov)
  • Concentrations of LDL with apoC-III (measured as apoB in this fraction) were associated with risk of coronary heart disease in multivariable analysis that included the ratio of total cholesterol to high-density lipoprotein cholesterol, LDL cholesterol, apoB, triglycerides, or high-density lipoprotein cholesterol and other risk factors. (harvard.edu)
  • Objective- We investigated the associations between plasma very-low-density lipoprotein (VLDL)-apolipoprotein (apo)C-III and apoA-V concentrations and the kinetics of VLDL-apoB-100 and VLDL triglycerides in 15 men. (ahajournals.org)
  • Methods and Results- ApoC-III, apoB, and triglyceride kinetics in VLDL were determined using stable isotopes and multicompartmental modeling to estimate production rate (PR) and fractional catabolic rate (FCR). (ahajournals.org)
  • Plasma VLDL-apoC-III concentration was significantly and inversely associated with the FCRs of VLDL triglycerides ( r =−0.610) and VLDL-apoB ( r =−0.791), and positively correlated with the PR of VLDL-apoC-III ( r =0.842). (ahajournals.org)
  • In multiple regression analysis, plasma VLDL-apoC-III concentration was a significant predictor of VLDL triglyceride FCR (β-coefficient=−0.575) and VLDL-apoB FCR (β-coefficient=−0.839). (ahajournals.org)
  • Conclusions- Our findings suggest that increased VLDL-apoC-III concentrations resulting from an overproduction of VLDL-apoC-III are strongly associated with the delayed catabolism of triglycerides and apoB in VLDL. (ahajournals.org)
  • 2 The metabolism of VLDL involves regulatory processes governing the turnover of triglycerides and apolipoprotein B-100 (apoB). (ahajournals.org)
  • Specifically, we examined the associations between plasma VLDL-apoC-III and apoA-V concentrations and the kinetics of VLDL triglycerides and VLDL-apoB. (ahajournals.org)
  • We determined whether two host defense factors that inhibit AIP1-induced agrI signaling, Nox2 and apolipoprotein B (apoB), also contribute to innate control of AIP3-induced agrIII signaling. (nih.gov)
  • This study suggests that the ApoC-III 3238CG heterozygotes benefited more from alcohol consumption than CC and GG homozygotes in increasing serum levels of HDL-C, ApoA-I, and the ratio of ApoA-I to ApoB, and lowering serum levels of TC and TG. (biomedcentral.com)
  • Serum traditional lipids (total, LDL, non-HDL, and HDL cholesterol and triglycerides) and apolipoprotein AI (apoAI), apolipoprotein B (apoB), and the apoB-to-apoAI ratio were assessed. (diabetesjournals.org)
  • Recently, there has been an interest in the relationship of apolipoprotein AI (apoAI) and apolipoprotein B (apoB) with diabetic retinopathy ( 5 , 8 , 9 ). (diabetesjournals.org)
  • ApoAI is an HDL constituent and apoB is present in VLDL, intermediate-density lipoprotein (IDL), LDL, and lipoprotein(a), and both apolipoproteins are not affected by prandial status ( 10 ). (diabetesjournals.org)
  • Detection of new ligand-defective mutations of apolipoprotein B (apoB) will enable identification of sequences involved in binding to the LDL receptor. (jci.org)
  • Amino acid sequences of tryptic peptides derived from affinity purified 70-kDa and 67-kDa rat BRF-3 proteins were found to have 100% sequence homologies with DNA topoisomerase I. These data suggest that the 70-kDa and 67-kDa forms of BRF-3 are derived by proteolytic cleavage of topoisomerase I, and therefore, topoisomerase I may play an important role in transcriptional regulation of apoB. (unthsc.edu)
  • Non-fasting samples were collected from 7260 healthy Chinese children and adolescents, and they were analysed using the Olympus AU5400 analyser for: triglycerides, total cholesterol (TC), high-density lipoprotein cholesterol, low-density lipoprotein cholesterol (LDL-C), apolipoprotein A1 and apolipoprotein B (ApoB). (bmj.com)
  • BACKGROUND: Compared to the epsilon 2 or epsilon 3 alleles, the epsilon 4 allele of apolipoprotein E (ApoE4) is associated with twice the prevalence of late-onset Alzheimer's disease (AD). (clinicaltrials.gov)
  • To determine the association between the e4 allele of apolipoprotein E and Alzheimer's disease in a randomly selected population sample. (bmj.com)
  • The prevalence of Alzheimer's disease was 2.9% in subjects with no e4 alleles, 7.6% in subjects with one e4 allele, and 21.4% in subjects with two e4 alleles of apolipoprotein E. (bmj.com)
  • Allele e4 of apolipoprotein is associated with Alzheimer's disease in a dose-response fashion in a randomly selected elderly population. (bmj.com)
  • RF 1-2* Evidence is accumulating that apolipoprotein E is important in late onset Alzheimer's disease. (bmj.com)
  • The first evidence that e4 allele of apolipoprotein E could be associated with Alzheimer's disease was published by Pericak-Vance et al. (bmj.com)
  • All the studies that have investigated the relation between apolipoprotein E polymorphism and Alzheimer's disease have included highly selected patients and corresponding controls. (bmj.com)
  • Verghese, P. B., Castellano, J. M. & Holtzman, D. M. Apolipoprotein E in Alzheimer's disease and other neurological disorders. (nature.com)
  • The method developed for apolipoprotein E genotyping is accurate and reliable, and also suitable for genotyping large samples, which may help determine the role of the apolipoprotein E ε4 allele in neural regeneration in late-onset Alzheimer's disease cases. (bio-medicine.org)
  • We found similar apolipoprotein E allelic frequencies and genotype distributions in both groups. (cdc.gov)
  • Apolipoprotein E Genotype and Temperament: A Longitudinal Study from Infancy to the Late Teens," Psychosomatic Medicine, Vol. 65, No. 4, 2003, pp. 662-664. (scirp.org)
  • We determined the effect of cafestol on serum cholesterol and triglycerides in different mouse strains and subsequently studied its mechanism of action in apolipoprotein (apo) E*3-Leiden transgenic mice. (tudelft.nl)
  • These increases were mainly due to a rise in very low density lipoprotein (VLDL) and intermediate density lipoprotein cholesterol in all 3 mouse strains. (tudelft.nl)
  • Unopposed conjugated equine estrogen (0.625 mg) lowered total cholesterol 4-8% and low-density lipoprotein (LDL) cholesterol 12-19% below pre-treatment levels in all three groups. (semanticscholar.org)
  • Familial Apolipoprotein A-I and C-III Deficiency is a lipid metabolism disorder characterized by low HDL cholesterol and a lack of apolipoproteins A-I and C-III in the blood. (rightdiagnosis.com)
  • Apolipoprotein C-III as a Potential Modulator of the Association Between HDL-Cholesterol and Incident Coronary Heart Disease. (thefreedictionary.com)
  • The study by Harvard School of Public Health (HSPH) researchers is the first research to show that a small protein, apolipoprotein C-III (apoC-III), that sometimes resides on the surface of HDL cholesterol may increase the risk of heart disease and that HDL cholesterol without this protein may be especially heart protective. (thefreedictionary.com)
  • Plasma apolipoprotein E phenotypes modulate lipoprotein concentrations, particularly that of low density lipoprotein cholesterol. (bmj.com)
  • The Ratio of High-Density Lipoprotein Cholesterol to Apolipoprotein A-I Predicts Myocardial Injury Following Elective Percutaneous Coronary Intervention. (medscape.com)
  • Prior studies have found inverse associations between high-density lipoprotein cholesterol (HDL-C) or apolipoprotein A-I levels and cardiovascular disease (CVD). (annals.org)
  • Whether this observation is consistent across low-density lipoprotein cholesterol (LDL-C) levels or total atherogenic particle burden (apolipoprotein B100) is less well-studied, particularly in women. (annals.org)
  • LDL-cholesterol (LDL- C), apolipoproteins (apo) B, CIII, and E, and by decreased levels of HDL-cholesterol (HDL-C), apoA-I, and lecithin:cholesterol acyltransferase (LCAT) activity. (tudelft.nl)
  • Apolipoprotein levels and ratios are more significant than LDL cholesterol levels in the prediction of fatal myocardial infarction. (greenmedinfo.com)
  • OBJECTIVE -Dysregulated apolipoprotein (apo)C-III metabolism may account for hypertriglyceridemia and increased cardiovascular risk in the metabolic syndrome. (diabetesjournals.org)
  • Hence, interventions that target apoC-III metabolism are clinically important. (diabetesjournals.org)
  • However, their effect on apoC-III metabolism in vivo is not known. (diabetesjournals.org)
  • Do Apolipoprotein E Polymorphisms Influence Risk of Cognitive Decline by Modulating Omega-3 Fatty Acid Metabolism? (clinicaltrials.gov)
  • Low-density lipoprotein (LDL) that contains apolipoprotein (apo) C-III makes up only 10% to 20% of plasma LDL but has a markedly altered metabolism and proatherogenic effects on vascular cells. (harvard.edu)
  • We also explored the relationship between these parameters of VLDL metabolism and VLDL-apoC-III kinetics. (ahajournals.org)
  • In the present study, we tested the hypothesis that apoC-III and apoA-V have opposing regulatory effects on VLDL metabolism. (ahajournals.org)
  • We studied the independent and combined effects of fish oils and atorvastatin on the metabolism of HDL apolipoprotein A-I (apo A-I) and HDL apo A-II in obese men. (nih.gov)
  • Apolipoprotein C-III (apoC-III) is a key regulator of lipoprotein metabolism. (ovid.com)
  • Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism. (thefreedictionary.com)
  • One explanation as to why APOE4 carriers may not benefit from fish intake is potentially linked with imbalances in omega-3 fatty acid metabolism. (clinicaltrials.gov)
  • DI-fusion Apolipoproteins C-II and C-III metabolism in. (ac.be)
  • Since lipid fusion should not be the physiological function of the N-terminal domain of apo CIII, we suggest that its peculiar distribution of hydrophobic residues is important for the lipid-binding properties of apo C-III and should be involved in apolipoprotein and lipid exchanges crucial for triglyceride metabolism. (ucl.ac.uk)
  • Lipoprotein (a) and Low-density lipoprotein apolipoprotein B metabolism following apheresis in patients with elevated lipoprotein(a) and coronary artery disease. (harvard.edu)
  • What is the role of apolipoprotein studies in the workup of cerebral amyloid angiopathy (CAA)? (medscape.com)
  • 4 proteins (complement factor H, apolipoprotein C-III precursor, complement C3 precursor, and [[alpha]. (thefreedictionary.com)
  • Systemic hereditary amyloidoses are disorders caused by mutant forms of plasma proteins such as transthyretin (TTR) or less frequently, apolipoprotein A-1 (apo A-1), the major protein in high-density lipoprotein (HDL). (diva-portal.org)
  • Using the models of two long anti-atherogenic and anti-inflammatory proteins (apolipoprotein A-I and apolipoprotein E with 243 and 299 amino acids, respectively) short mimetic peptides of 18 to 28 amino acid residues in length, which can be produced either synthetically or genetically in edible fruits and vegetables, have been shown to exert profound biological effects in a large number of animal models of diseases. (springer.com)
  • The proteins apolipoprotein (apo) A-I, apoL-I, and haptoglobin-related protein, which are involved in TLF structure and function, were expressed through the introduction of transgenes in mice to explore their physiological roles in vivo. (rupress.org)
  • Coexpression of human apolipoprotein A-I and haptoglobin-related protein (Hpr) had an effect on the integration of apolipoprotein L-I into HDL, and both proteins were required to increase the specific activity of TLF, which was measurable in vitro. (rupress.org)
  • Apolipoprotein A-I (apoA-I) is the defining component of all HDLs, which, along with different combinations of proteins, confer many functions to HDLs, the best known being atheroprotection ( 1 ). (rupress.org)
  • Both 70-kDa and 67-kDa proteins have been found to hybridize specifically with labeled double- stranded oligonucleotide containing BRF-3 binding site in a South-Western blot. (unthsc.edu)
  • Double-stranded oligonucleotide containing mutations in the BRF-3 binding site was found to abolish DNA binding by these two proteins. (unthsc.edu)
  • Dose-response effects of marine omega-3 fatty acids on apolipoproteins, apolipoprotein-defined lipoprotein subclasses, and Lp-PLA2 in individuals w. (nih.gov)
  • Little evidence exists regarding the dose-response effects of the marine omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on apos, apo-defined Lps, and Lp-PLA2. (nih.gov)
  • Epidemiological studies show that risk of AD varies inversely with consumption of omega-3 fatty acids from fish and seafood. (clinicaltrials.gov)
  • Blood omega-3 fatty acids was evaluated monthly during the supplementation period. (clinicaltrials.gov)
  • In order to test whether hyperlipidaemia and glycaemic control can be improved among diabetes patients by dietary supplementation with purified omega-3 fatty acids, we carried out a double-blind, placebo-controlled trial on 50 type 2 diabetes patients randomized to 2 g/day purified omega-3 fatty acids or placebo for 10 weeks. (who.int)
  • Omega-3 fatty acids had no significant effect on serum lipid levels, ApoA-I, glucose, insulin and HbA1c. (who.int)
  • Omega 3 fatty acids induce a marked reduction of apolipoprotein B48 when added to fluvastatin in patients with type 2 diabetes and mixed hyperlipidemia. (greenmedinfo.com)
  • Niacin and omega-3 fatty acids may correct non-HDL lipoprotein and apolipoprotein B abnormalities. (greenmedinfo.com)
  • The lipid-interacting properties of the N-terminal domain of human apolipoprotein C-III (apo C-III) were investigated. (ucl.ac.uk)
  • The importance of apolipoprotein E genotypes and allelic polymorphisms in the etiology of recurrent miscarriage is controversial. (cdc.gov)
  • Association of Apolipoprotein E Genotypes with Lipid Levels and Coronary Risk," Journal of the American Medical Association, Vol. 298, No. 11, 2007, pp. 1300-1311. (scirp.org)
  • Genetic factors contributing to the expression of type III HLP were investigated in 113 hyper- and 52 normolipidemic E2/2 subjects, by testing for polymorphisms in APOC3, APOA5, HL (hepatic lipase) and LPL (lipoprotein lipase) genes. (tudelft.nl)
  • G polymorphisms are associated with TG levels in overweight/obese Chinese subjects and that the two polymorphisms are also associated with certain lipid and apolipoprotein variations, depending on BMI. (biomedcentral.com)
  • Polymorphisms in lipolysis genes associate with the expression and severity of type III HLP in APOE2/2. (tudelft.nl)
  • Apolipoprotein E genotyping is crucial to apolipoprotein E polymorphism analysis. (bio-medicine.org)
  • Peripheral venous blood is the conventional tissue source for apolipoprotein E genotyping polymorphism analysis. (bio-medicine.org)
  • More detailed information about the symptoms , causes , and treatments of Familial Apolipoprotein A-I and C-III Deficiency is available below. (rightdiagnosis.com)
  • Deficiency or defects in Apo E are causes of HYPERLIPOPROTEINEMIA TYPE III. (harvard.edu)
  • All variants were able to remodel multillamelar 1,2-Dimyristoyl-sn-glycero-3-phosphocholine (DMPC) vesicles, but R136S and R145C had reduced kinetics. (nih.gov)
  • Clinical data suggest that eicosapentaenoic acid (EPA) alone, which lowers triglycerides to a similar extent as EPA + DHA, does not raise LDL-C, but also fails to lower apoC-III. (ahajournals.org)
  • Compelling experimental and molecular data suggest that apoA-V reduces plasma triglycerides by 3 potential mechanisms: inhibition of VLDL production, stimulation of LPL-mediated VLDL triglyceride hydrolysis, and acceleration of hepatic uptake of VLDL particles. (ahajournals.org)
  • ApoC-III inhibits LPL activity and TRL remnant uptake by hepatic lipoprotein receptors ( 4 ). (diabetesjournals.org)
  • ApoC-III likely inhibits LPL by competing for lipid binding. (diva-portal.org)
  • AKCEA-APOCIII-LRx inhibits the production of apolipoprotein C-III (ApoC-III) for the broad population of patients who have cardiometabolic disease due to their elevated triglyceride levels and ApoC-III. (thefreedictionary.com)
  • RESULTS -Compared with placebo, there was a significant dose-dependent reduction with rosuvastatin in plasma triglyceride and VLDL apoC-III concentrations. (diabetesjournals.org)
  • In normolipidemic subjects, the majority of plasma apoC-III is bound to HDL, while in hypertriglyceridemic subjects, the majority is bound to TRL ( 4 ). (diabetesjournals.org)
  • Elevated plasma apoC-III concentration, and specifically its accumulation in TRL and their remnants, is causally related to hypertriglyceridemia in the metabolic syndrome ( 6 ). (diabetesjournals.org)
  • Furthermore, insulin resistance is associated with elevated plasma apoC-III concentrations ( 7 ). (diabetesjournals.org)
  • Animal studies suggest that statins decrease apoC-III hepatic mRNA expression and plasma concentrations via the peroxisome proliferator-activated receptor-α pathway ( 9 , 10 ). (diabetesjournals.org)
  • iii) Better cognitive performance occurs while on EPA+DHA and is linked to raising plasma EPA and/or DHA. (clinicaltrials.gov)
  • We examined the association between plasma LDL with apoC-III and coronary heart disease in 320 women and 419 men initially free of cardiovascular disease who developed a fatal or nonfatal myocardial infarction during 10 to 14 years of follow-up and matched controls who remained free of coronary heart disease. (harvard.edu)
  • In 399 patients with severe HTG we evaluated the effects on plasma apoC-III levels and the correlations between change in apoC-III and change in plasma lipids (TG, LDL-C) after 12-weeks of therapy. (ahajournals.org)
  • Plasma apoC-III levels correlate with triglyceride (TG) levels and are a strong predictor of CVD outcomes. (diva-portal.org)
  • 3 Elevated apoC-III, in particular VLDL-apoC-III, may induce hypertriglyceridemia because of accumulation in plasma of TRLs, and this could relate to oversecretion of VLDL-apoC-III. (ahajournals.org)
  • 5 Using stable isotopes and multicompartmental modeling, we have previously found that in overweight and obese men, increased plasma apoC-III concentration was associated with reduced catabolism of TRLs. (ahajournals.org)
  • Modulation of hepatic apolipoprotein B, 3-hydroxy-3-methylglutaryl-CoA reductase and low-density lipoprotein receptor mRNA and plasma lipoprotein concentrations by defined dietary fats. (biochemj.org)
  • Native Apolipoprotein C-III from human plasma found in VLDL and chylomicrons. (merckmillipore.com)
  • Native apolipoprotein C-III from human plasma. (merckmillipore.com)
  • Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration. (thefreedictionary.com)
  • Plasma proprotein convertase subtilisin/ kexin type 9: a marker of LDL apolipoprotein B-100 catabolism? (thefreedictionary.com)
  • Scavenger receptor function of mouse Fcγ receptor III contributes to progression of atherosclerosis in apolipoprotein E hyperlipidemic mice. (sigmaaldrich.com)
  • Our data highlight the beneficial impact of n-3 fatty acids on adverse effects of the metabolic syndrome and emphasise their influence on intestinal lipid transport, an effect which may limit postprandial lipaemia and the risk of atherosclerosis. (ovid.com)
  • Hypertension, atherosclerosis and aortic aneurysm were induced by subcutaneous infusion of angiotensin II (1 μg/kg/min) for 28 days in apolipoprotein E-deficient mice. (frontiersin.org)
  • RDN promoted atherosclerosis in apolipoprotein E-deficient mice infused with angiotensin II associated with upregulation of MMP-2. (frontiersin.org)
  • Fibrinogen alpha chain precursor and apolipoprotein a-I in urine as biomarkers for noninvasive diagnosis of calcium oxalate nephrolithiasis: a proteomics study. (medscape.com)
  • We therefore tested the hypothesis that n-3 fatty acids improve the various events governing intra-enterocyte lipid transport in Psammomys obesus gerbils, a model of nutritionally induced metabolic syndrome. (ovid.com)
  • Rather, the suppressed production of apo B-48 by n-3 fatty acids was associated with intracellular proteasome-mediated posttranslational downregulation in insulin-resistant and diabetic animals. (ovid.com)
  • Epidemiological studies suggest a protective role of omega-3 poly-unsaturated fatty acids (n-3 PUFA) against Alzheimers disease (AD). (eurekaselect.com)
  • Familial ligand-defective apolipoprotein B. Identification of a new mutation that decreases LDL receptor binding affinity. (jci.org)
  • Alzheimers Is Genetic Protect Your Future www.alzheimer-herbs.com/ Apolipoprotein alzheimers disease connection The scientific enthusiasm about the possible role of amyloid protein in the pathology of Alzheimers disease has been further fueled by the results of molecular genetics studies that have identified genes associated with familial (inherited) Alzheimers disease on chromosomes 21, 14, 1, and 19. (slideshare.net)
  • The effects of conjugated equine estrogen and subsequent cyclical progestogen supplementation on lipoprotein and apolipoprotein A-I levels were investigated in three groups of postmenopausal women. (semanticscholar.org)
  • In this study a series of Sicilian neonates was studied in order to investigate about the distribution of serum lipid and apolipoprotein at birth and the differences with adults. (springer.com)
  • In conclusion lipid and apolipoprotein distributions in Sicilian newborns are not different from that of other population and there are no differences between males and females. (springer.com)
  • The aim of this study was to establish age-specific and gender-specific reference intervals for non-fasting lipids and apolipoproteins in healthy Chinese children and adolescents. (bmj.com)
  • Paediatric reference intervals were established for non-fasting lipids and apolipoproteins based on a large population of healthy children and adolescents. (bmj.com)
  • After three months of treatment, all mice were tested in the Morris water maze. (aging-us.com)
  • RDN decreased systolic blood pressure in apolipoprotein E-deficient mice. (frontiersin.org)
  • Here, we studied the role of LPL and two potent modifiers, the LPL inhibitor apoC-III and the LPL activator apoA-V, in APOE2-knockin (APOE2) mice. (tudelft.nl)
  • Apolipoprotein (apo)-C-III is an 8.8-kDa glycoprotein synthesized by the liver and intestines. (diabetesjournals.org)
  • Primary structure of the bovine analogues to human apolipoproteins CII and CIII. (wikipedia.org)
  • We conclude that all three human apolipoproteins act cooperatively to achieve maximal killing capacity and that truncated apolipoprotein L-I does not function in transgenic animals. (rupress.org)
  • Genetic Epidemiology , 14 (3), 265-82. (unboundmedicine.com)
  • Trypanosome subspecies expressing the serum resistance-associated protein (SRA), either naturally ( Trypanosoma brucei rhodesiense ) or via genetic modification ( Trypanosoma brucei brucei-SRA ), are resistant to lysis by TLF ( 3 ) because SRA purportedly binds apoL-I and neutralizes TLF activity or redirects TLF intracellular trafficking to prevent lysis ( 3 , 7 ). (rupress.org)
  • Apolipoprotein CIII is also found on HDL particles. (wikipedia.org)
  • Since EPA alone does not appear to lower apoC-III, these results support the hypothesis that DHA has specific effects in lowering apoC-III and that the mechanism by which DHA increases LDL-C may be related to its effect to lower apo CIII. (ahajournals.org)
  • The A-I and A-IV genes are transcribed from the same strand, while the A-1 and C-III genes are convergently transcribed. (wikipedia.org)
  • The present invention relates to methods of use of phosphonate-phosphates and diphosphonates to modulate apolipoprotein E levels and the use of such compounds in therapy, including cardiovascular and neurological disease states. (freepatentsonline.com)
  • In this study we examined whether three type III HLP predisposing apoE3 variants, namely R136S, R145C and K146E affect the biophysical properties of the protein. (nih.gov)
  • Apolipoprotein E2 (apoE2)-associated hyperlipidemia is characterized by a disturbed clearance of apoE2-enriched VLDL remnants. (tudelft.nl)
  • L. Pulkki-Råback, M. Elovainio, M. Kivimäki, O. T. Raitakari and L. Keltikangas-Järvinen, "Temperament in Childhood Predicts Body Mass in Adulthood: The Cardiovascular Risk in Young Finns Study," Health Psychology, Vol. 24, No. 3, 2005, pp. 307-315. (scirp.org)
  • CONCLUSIONS -In this study, rosuvastatin decreased the production and increased the catabolism of VLDL apoC-III, a mechanism that accounted for the significant reduction in VLDL apoC-III and triglyceride concentrations. (diabetesjournals.org)
  • To identify the mechanisms by which cocoa induces HDL levels and since apolipoprotein AI (ApoAI) is the major protein in HDLs, we analyzed, upon incubation with cocoa metabolites, ApoAI mRNA levels, its transcriptional regulation, and the levels of the transcription factors involved in this process. (wiley.com)
  • Incubation with 3-methyl-epicatechin led to an increase in HNF-3β mRNA, HNF-3β, ER-α, Sp1, and NFY protein levels and the activation of ApoAI transcription mediated by NFY, Sp1, and ER-α. (wiley.com)
  • Hepatic levels of 3-hydroxy-3-methylglutaryl-CoA reductase mRNA did not vary significantly between the groups. (biochemj.org)
  • 3, 4 Furthermore, phenotypes E4/4 and E4/3 have been associated with the risk of myocardial infarction and coronary heart disease,*RF 5-7* particularly in young people, although there is some controversy about this. (bmj.com)
  • Lipoprotein (a) concentrations, apolipoprotein (a) phenotypes, and peripheral arterial disease in three independent cohorts. (cdc.gov)
  • Analyses in three independent populations showed significant associations of Lp(a) concentrations, LMW apo(a) phenotypes, and rs10455872 with PAD. (cdc.gov)
  • As assessed in cultured jejunal explants incubated with either [14C]-oleic acid or [35S]-methionine, fish oil feeding resulted in diminished triglyceride-rich lipoprotein assembly and apolipoprotein (apo) B-48 biogenesis, respectively. (ovid.com)
  • This study investigated the dose-dependent effect of rosuvastatin on VLDL apoC-III transport in men with the metabolic syndrome. (diabetesjournals.org)
  • VLDL apoC-III kinetics were examined using a stable isotope method and compartmental modeling at the end of each intervention period. (diabetesjournals.org)
  • 6 However, we did not examine the association with VLDL triglyceride kinetics or the role of VLDL-apoC-III kinetics. (ahajournals.org)
  • an apolipoprotein found in VLDL, HDL, and chylomicrons. (thefreedictionary.com)
  • Other atherogenic lipoprotein particles, including chylomicron and VLDL remnants, abnormal remnant composition, and increased apolipoprotein C-III complicate the metabolic syndrome picture as well, said Dr. (thefreedictionary.com)
  • Minor apolipoprotein mainly associated with HDL and to a lesser extent with VLDL. (abcam.com)
  • We used immunoaffinity chromatography to measure the apoA-I concentrations of HDL that contains and lacks apoC-III in 2 prospective studies of adults free of CHD. (ovid.com)
  • An intervention study showed that only non-carriers had increased concentrations of long-chain n-3 PUFA in response to supplementation. (eurekaselect.com)
  • Synthetic peptide within Human Apolipoprotein A I aa 1-100 (N terminal). (abcam.com)
  • Since most tilted peptides were shown to induce liposome fusion in vitro, the fusogenic capacity of the 6-20 fragment of apo C-III was tested on unilamellar liposomes and compared with the well characterized SIV fusion peptide. (ucl.ac.uk)
  • Lipid-mixing experiments showed that the apo C-III (6-20) peptide is able to increase the fluorescence of a lipophilic fluorescent probe. (ucl.ac.uk)
  • The apo C-III (6-20) fragment is, however, less fusogenic than the SIV peptide, in agreement with their respective mean hydrophobicity. (ucl.ac.uk)
  • Association of Apolipoprotein E in Lipoprotein Subspecies With Risk of Dementia. (harvard.edu)
  • Biophysical analysis of apolipoprotein E3 variants linked with development of type III hyperlipoproteinemia. (nih.gov)
  • Type III hyperlipoproteinemia (HLP) is mainly found in homozygous apolipoprotein (APO) E2 (R158C) carriers. (tudelft.nl)
  • In circulation, apoC-III is associated with TRL and HDL, exchanging rapidly between these particles ( 5 ). (diabetesjournals.org)
  • It does not interchange between lipoprotein particles, as do the other apolipoproteins, and it is found in IDL and LDL after the removal of the Apo-A, E, and C. Apo-B48 is present in chylomicrons and their remnants. (sigmaaldrich.com)
  • Apolipoprotein CII (apoCII) is a protein found in large fat particles that the gastrointestinal tract absorbs. (medlineplus.gov)
  • corresponding hazard ratios for apolipoprotein A-I were 1.00 (reference), 0.98 (CI, 0.71 to 1.35), 1.02 (CI, 0.72 to 1.44), 1.37 (CI, 0.98 to 1.90), and 1.58 (CI, 1.14 to 2.20) ( P for linear trend = 0.005). (annals.org)